Abstract
Achyranthes bidentata Blume (ABB; Chinese name: Huai Niuxi) and Cyathula officinalis K.C.Kuan (COK; Chinese name: Chuan Niuxi), two botanical drugs collectively termed “Niuxi” in traditional Chinese medicine (TCM), are widely used for rheumatoid arthritis (RA) management. This review comprehensively summarized the pharmacological mechanisms and therapeutic potential of the metabolites of ABB and COK on RA, while addressing limitations of current evidence. Of the 314 and 185 metabolites contained in ABB and COK, respectively, 22 metabolites (including Chikusetsusaponin V and chikusetsusaponin Ⅳa), showed multiple anti-RA activities. The mechanisms underlying the effects of ABB and COK with respect to the occurrence and development of RA (including inflammatory processes, immunoregulation, fibroblast-like synoviocytes, angiogenesis, oxidative stress, cartilage degradation, and bone destruction) were evaluated (Graphical Abstract). Numerous signaling pathways, such as the nuclear factor kappa-B (NF-κB), mitogen-activated protein kinase (MAPK), and phosphoinositide 3-kinase/protein kinase B (PI3K/AKT), are involved in RA. The metabolites contained in ABB and COK have significant medicinal value and potential in the treatment of RA, while in-depth mechanism studies and clinical research are warranted to support the clinical application of these metabolites.

1 Introduction
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by synovial inflammation, affecting approximately 1% of the population worldwide (van der Woude and van der Helm-van Mil, 2018). In the absence of treatment, RA can result in severe joint loss, deformity, and a high mortality rate (Babiker-Mohamed et al., 2024). Current treatments include non-steroidal anti-inflammatory drugs, glucocorticoids, disease-modifying antirheumatic drugs, and other immuno-modifiers (Baig et al., 2024). Although these drugs are effective against RA, approximately 40% of patients do not achieve clinical remission (Gao et al., 2024). Thus, there is an urgent need to development more efficacious anti-RA agents. Traditional Chinese medicine (TCM) has recently gained considerable attention due to the low cost, good safety profile, and multi-targeting nature of its medications (Wang et al., 2024a). TCM may be an important complementary medical strategy for RA.
“Niuxi” is one of the most commonly used medications in the TCM treatment of RA, with effects such as tonifying the liver and kidneys, strengthening muscles and bones, and relieving swelling and pain (Gao et al., 2013; Liu et al., 2013). Over 100 prescriptions for treating RA contain “Niuxi”, including Biqi capsule (Lv et al., 2023), Sanhan Chushi decoction (Ma et al., 2024), Qushi Zhitong Pills (Zhang et al., 2023). A meta-analysis of 15 studies involving 1,636 patients with RA showed that, compared with Western medicine, treatment with “Niuxi” and other TCMs, markedly increased the total effective rate and reduced the number of swollen joints, number of painful joints, rheumatoid factor (RF) levels, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) levels (Lv et al., 2023). In a randomized controlled trial, compared to methotrexate and leflunomide, treatment with “Niuxi” and other TCMs combined with methotrexate and leflunomide in patients with RA obviously decreased CRP levels, ESR, tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-17, RF, matrix metalloproteinase-3 (MMP-3) and transforming growth factor-β (TGF-β) (Chen et al., 2024). The National Medical Products Administration also approved numerous Chinese Patent Medicines containing “Niuxi” (e.g., Biqi capsules, Yuxuebi capsules, and Jishengshenqi pills) for the treatment of RA. A Bayesian network meta-analysis of 16 randomized controlled trials involving 10,213 patients with RA showed that Biqi capsules, Yuxuebi capsules, and glucosides of Tripterygium Wilfordii tablets were recommended for treating RA according to their clinical efficacy (Zhang et al., 2020a). Achyranthes bidentata Blume (ABB; Chinese name: Huai Niuxi) and Cyathula officinalis K.C.Kuan (COK; Chinese name: Chuan Niuxi) are both used as ‘Niuxi’. ABB and COK have been widely used to treat patients with RA in combination with other botanical drug, some of which are listed in Table 1.
TABLE 1
| Prescription name | Study design | Patients, treatment and duration | Outcome measures | Results | References |
|---|---|---|---|---|---|
| Biqi Capsules (痹祺胶囊)a | Randomized controlled trial | 70 (1:1, the control group: Leflunomide and Methotrexate group; the observation group: Biqi Capsules and Methotrexate group) 24 weeks | 20% improvement in ACR criteria (ACR20) | 81.2% patients in Biqi group achieved ACR20 at 24 weeks. There were no significant differences in primary or secondary outcomes between the two groups | Wang et al. (2020) |
| Randomized controlled trial | 200 (1:1, the control group: Etoricoxib Tablets; the observation group: Etoricoxib Tablets and Biqi Capsules) 12 weeks | Total clinical effective (joint pain, morning stiffness, and swelling); CRP, RF, anti-streptolysin O (ASO), ESR, IgA, IgG, IgM, complement C3 and C4 | The total clinical effective rate of observation group (83.00%) was significantly higher than control group (69.00%) | Liu et al. (2021b) | |
| Yuxuebi Tablets (瘀血痹片)b | Randomized controlled trial | 122 (1:1, the control group: Methotrexate Tablets; the observation group: Methotrexate Tablets and Yuxuebi Tablets) 12 weeks | LKSS, VAS, activies of daily living (ADL), IL-1, TNF-α, intercellular adhesion molecule-1 (ICAM-1) | The total effective rate of the observation group (93.44%) was higher than that of the control group (78.69%) | Fang et al. (2019) |
| Angelicae pubescentis and Loranthi Pills (独活寄生丸)c | Randomized controlled trial | 120 (1:1:1, the control group: Celecoxib Capsules; the observation group 1: Angelicae pubescentis and Loranthi Pills; te observation group 2: Celecoxib Capsules and Angelicae pubescentis and Loranthi Pills) 14 days | IL-6 and TNF-α | It was significantly lower in the observation group 2 than that in the control group and observation group 1, and there was no statistical significance on the difference between observation group 1 and control group | Ding et al. (2021) |
| Tongbi Tablets (通痹片)d | Randomized controlled trial | 132 (1:1, the control group: Celecoxib Capsules; the observation group: Celecoxib Capsules and Tongbi Tablets) 12 weeks | VAS, WOMAC and inflammatory cytokines (IL-1, TNF-α, ICAM-1) | The total effective rate of the observation group (95.45%) was higher than that of the control group (78.79%) | Su et al. (2020) |
| Tongbi Capsules (通痹胶囊)d | Randomized controlled trial | 90 (1:1, the control group: Methotrexate Tablets and Leflunomide; the observation group: Methotrexate Tablets, Leflunomide and Tongbi Capsules) 4 months | Microcirculation index [resistance index (RI), end diastolic velocity (EDV), peak systolic velocity (PSV)], MMP-1, MMP-3, RF, CRP, ESR, ASO | The total effective rate of the observation group (95.56%) was higher than that of the control group (82.22%) | Li et al. (2020) |
| Fengshi Maqian Tablets (风湿马钱片)e | Retrospective study | 84 (the control group: Methotrexate Tablets; the observation group: Methotrexate Tablets and Fengshi Maqian Tablets) 12 weeks | Joint pain, morning stiffness, and swelling; the levels of CRP, IL-17, TNF-α, COX-2 and Tumor necrosis factor-like ligand 1A (TL1A) | The total effective rate of the observation group (90.48%) was higher than that of the control group (71.43%) | Liu (2017) |
| Modified Simiao Pills (四妙丸加味)f | Retrospective study | 92 (the control group: Leflunomide; the observation group: Leflunomide and Modified Simiao Pills) 1 month | DAS28, VAS, morning stiffness time, tenderness index and IL-1β, IL-6, TNF-α, ESR, PV (plasma viscosity), PCV (packed cell volume), IgG, IgA, IgE, CRP, RF | The total effective rate of the observation group (91.30%) was higher than that of the control group (78.26%) | Zhang et al. (2020b) |
| San Miao San (三妙散)g | Double-blind, randomized, placebo-controlled study | the TCM group (combination of Ganoderma lucidum (4 gm) and San Miao San (2.4 gm) daily) 32 cases and the placebo control group 33 cases 24 weeks | ACR20, plasma levels (percentage, absolute counts, and CD4+/CD8+/natural killer/B lymphocytes ratio, IL-18, INF-γ, MCP-1, RANTES) | 15% in the TCM group compared with 9.1% in the placebo group achieved ACR20 (P > 0.05). Pain score and patient’s global score improved significantly only in the TCM group. The plasma levels were unchanged | Li et al. (2007a) |
Classical prescriptionss of ABB or COK for treating RA in China.
Strychnos nux-vomica L. [Loganiaceae, Strychni semen] 24.84 g, Pheretima aspergillum (E. Perrier) [Megascolecidae, Pheretima] 2.48 g, Codonopsis pilosula (Franch.) Nannf. [Campanulaceae, Codonopsis radix] 37.27 g, Poria cocos (Schw.) Wolf [Smilacaceae, Poria] 37.27 g, Atractylodes macrocephala Koidz. [Asteraceae, Atractylodis macrocephalae rhizoma] 37.27 g, Glycyrrhiza glabra L. [Fabaceae, Glycyrrhizae radix et rhizoma] 37.27 g, Conioselinum anthriscoides ‘Chuanxiong’ [Apiaceae, Chuanxiong rhizoma] 49.69 g, Salvia miltiorrhiza Bunge [Lamiaceae, Salviae miltiorrhizae radix et rhizoma] 24.84 g, Panax notoginseng (Burkill) F.H.Chen [Araliaceae, Notoginseng radix et rhizoma] 24.84 g, and Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix]24.84 g.
Boswellia sacra Flück. [Burseraceae, Olibanum], Clematis chinensis Osbeck [Ranunculaceae, Clematidis radix et rhizoma], Carthamus tinctorius L. [Asteraceae, Carthami flos], Salvia miltiorrhiza Bunge [Lamiaceae, Salviae miltiorrhizae radix et rhizoma], Commiphora myrrha (T.Nees) Engl. [Burseraceae, Myrrha], Cyathula officinalis K.C.Kuan [Amaranthaceae, Cyathulae radix], Conioselinum anthriscoides ‘Chuanxiong’ [Apiaceae, Chuanxiong rhizoma], Angelica sinensis (Oliv.) Diels [Apiaceae, Angelicae sinensis radix], Curcuma longa L. [Zingiberaceae, Curcumae longae rhizoma], Cyperus rotundus L. [Cyperaceae, Cyperi rhizoma], and Astragalus mongholicus Bunge [Fabaceae, Astragali radix] (dosage information is not available).
Angelica biserrata (R.H.Shan and C.Q.Yuan) C.Q.Yuan and R.H.Shan [Apiaceae, Angelicae pubescentis radix]54 g, Taxillus chinensis (DC.) Danser [Loranthaceae] 54 g, Gentiana macrophylla Pall. [Gentianaceae, Gentianae macrophyllae radix] 54 g, Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk. [Apiaceae, Saposhnikoviae radix] 54 g, Asarum heterotropoides F.Schmidt [Aristolochiaceae, Asari radix et rhizoma] 54 g, Angelica sinensis (Oliv.) Diels [Apiaceae, Angelicae sinensis radix] (wine-processed) 80 g, Paeonia lactiflora Pall. [Paeoniaceae, Paeoniae radix alba] 36 g, Conioselinum anthriscoides ‘Chuanxiong’ [Apiaceae, Chuanxiong rhizoma] 54 g, Rehmannia glutinosa (Gaertn.) DC. [Orobanchaceae, Rehmanniae radix] 36 g, Eucommia ulmoides Oliv. [Eucommiaceae, Eucommiae cortex] (stir-frying with salt) 54 g, Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix] 54 g, Codonopsis pilosula (Franch.) Nannf. [Campanulaceae, Codonopsis radix] 54 g, Poria cocos (Schw.)Wolf. [Smilacaceae, Poria] 54 g, Glycyrrhiza glabra L. [Fabaceae, Glycyrrhizae radix et rhizoma] 36 g, and Neolitsea cassia (L.) Kosterm. [Lauraceae, Cinnamomi cortex] 54 g.
Scolopendra subspinipes mutilans L. Koch. [Scolopendridae, Scolopendra] 4.42 g, Buthus martensii Karsch [Buthidae, Scorpio] 4.42 g, Pheretima aspergillum (E. Perrier) [Megascolecidae, Pheretima] 4.42 g, Bombyx mori Linnaeus [Bombycidae, Bombyx batryticatus] 4.42 g, Zoacys dhumnades [Colubridae, Zaocys] 4.42 g, Gastrodia elata Blume [Orchidaceae, Gastrodiae rhizoma] 4.42 g, Panax ginseng C.A.Mey. [Araliaceae, Ginseng radix et rhizoma]1.48 g, Astragalus mongholicus Bunge [Fabaceae, Astragali radix]17.72 g, Angelica sinensis (Oliv.) Diels [Apiaceae, Angelicae sinensis radix] 26.56 g, Hansenia weberbaueriana (Fedde ex H.Wolff) Pimenov and Kljuykov [Apiaceae, Notopterygii rhizoma et radix] 4.42 g, Angelica biserrata (R.H.Shan and C.Q.Yuan) C.Q.Yuan and R.H.Shan [Apiaceae, Angelicae pubescentis radix]4.42 g, Saposhnikovia divaricata (Turcz. ex Ledeb.) Schischk. [Apiaceae, Saposhnikoviae radix] 4.42 g, Ephedra sinica Stapf [Ephedraceae, Ephedrae herba] 4.42 g, Neolitsea cassia (L.) Kosterm. [Lauraceae, Cinnamomi cortex] 4.42 g, Aconitum carmichaelii Debeaux [Ranunculaceae, Aconiti lateralis radix praeparaia] 4.42 g, Coix lacryma-jobi var. ma-yuen (Rom.Caill.) Stapf [Poaceae, Coicis semen]126.56 g, Prunus persica (L.) Batsch [Rosaceae, Persicae semen] 8.86 g, Carthamus tinctorius L. [Asteraceae, Carthami flos] 5.90 g, Commiphora myrrha (T.Nees) Engl. [Burseraceae, Myrrha] 4.42 g, Manis 4.42 g, Corydalis yanhusuo (Y.H.Chou and Chun C.Hsu) W.T.Wang ex Z.Y.Su and C.Y.Wu [Papaveraceae, Corydalis rhizoma] (vinegar-processed) 4.42 g, Paeonia × suffruticosa Andrews [Paeoniaceae, Moutan cortex] 4.42 g, Gypsophila vaccaria (L.) Sm. [Caryophyllaceae, Vaccariae semen] 4.42 g, Piper kadsura (Choisy) Ohwi [Piperaceae, Piperis kadsurae caulis] 8.86 g, Cyperus rotundus L. [Cyperaceae, Cyperi rhizoma] (wine-processed) 4.42 g, Dolomiaea costus (Falc.) Kasana and A.K.Pandey [Asteraceae, Aucklandiae radix] 4.42 g, Citrus × aurantium f. aurantium [Rutaceae, Citri reticulatae pericarpium] 4.42 g, Wurfbainia villosa (Lour.) Škorničk. and A.D.Poulsen [Zingiberaceae, Amomi fructus] 3.70 g, Liquidambar formosana Hance [Altingiaceae, Liquidambaris resina] 4.42 g, Chaenomeles speciosa (Sweet) Nakai [Rosaceae, Chaenomelis fructus] 4.42 g, Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix] 4.42 g, Dipsacus asper Wall. ex DC. [Caprifoliaceae, Dipsaci radix] 4.42 g, Lycopodium clavatum L. [Lycopodiaceae, Lycopodii herba] 4.42 g, Rheum palmatum L. [Polygonaceae, Rhei radix et rhizoma] 4.42 g and Cinnabaris [Sulfides, Cinnabaris] 4.42 g.
Strychnos nux-vomica L. [Loganiaceae, Strychni semen], Bombyx mori Linnaeus [Bombycidae, Bombyx batryticatus], Boswellia sacra Flück. [Burseraceae, Olibanum], Commiphora myrrha (T.Nees) Engl. [Burseraceae, Myrrha], Buthus martensii Karsch [Buthidae, Scorpio], Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix], Atractylodes lancea (Thunb.) DC. [Asteraceae, Atractylodis rhizoma], Ephedra sinica Stapf [Ephedraceae, Ephedrae herba], Glycyrrhiza glabra L. [Fabaceae, Glycyrrhizae radix et rhizoma] (dosage information is not available).
Phellodendron chinense C.K.Schneid. [Rutaceae, Phellodendri chinensis cortex] 10–15 g, Atractylodes lancea (Thunb.) DC. [Asteraceae, Atractylodis rhizoma] 10–15 g, Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix]15–30 g, Coix lacryma-jobi var. ma-yuen (Rom.Caill.) Stapf [Poaceae, Coicis semen] 15–30 g. According to the specific situation of patients, Chaenomeles speciosa (Sweet) Nakai [Rosaceae, Chaenomelis fructus], Gentiana macrophylla Pall. [Gentianaceae, Gentianae macrophyllae radix], Carthamus tinctorius L. [Asteraceae, Carthami flos], Angelica sinensis (Oliv.) Diels [Apiaceae, Angelicae sinensis radix], Conioselinum anthriscoides ‘Chuanxiong’ [Apiaceae, Chuanxiong rhizoma], Boswellia sacra Flück. [Burseraceae, Olibanum], Piper kadsura (Choisy) Ohwi [Piperaceae, Piperis kadsurae caulis], Clematis chinensis Osbeck [Ranunculaceae, Clematis chinensis Osbeck] were added.
Atractylodes lancea (Thunb.) DC. [Asteraceae, Atractylodis rhizoma], Phellodendron amurense Rupr. [Rutaceae, Phellodendri chinensis cortex], Achyranthes bidentata Blume [Amaranthaceae, Achyranthis bidentatae radix] (dosage information is not available).
COK, the root of C. officinalis Kuan, is traditionally thought to have anti-blood stasis (Cao et al., 2017), anti-inflammation (Yang et al., 2022), and hepatoprotective properties (Meng et al., 2019); in addition, it is used in the treatment of orthopedic diseases (Park et al., 2011). Huang et al. reported that COK impacts the hematologic, urogenital, and immune systems (Huang et al., 2019). The chemical metabolites contained in COK can be roughly divided into triterpenoid saponins, steroid ketones, polysaccharides, and others (Liang et al., 2022). Current pharmacologic studies of COK have primarily focused on cyasterone, achyranthan and polysaccharides (Han et al., 2015; Feng et al., 2019; Yang et al., 2022).
ABB, the dry root of A. bidentata (A.bidentata) and Achyranthes aspera Linn (A. aspera), prevents osteoporosis (Jiang et al., 2014b), exerts neurotrophic and neuroprotective effects (Wang et al., 2013), inhibits myocardial ischemic/reperfusion-induced injuries (Tie et al., 2013) and possesses antitumor properties (Zhong et al., 2020). A. aspera aqueous extract offers significant protection against arthritis and joint inflammation (Chinnasamy et al., 2019). Researchers have found that RA is related to excessive osteoclast resorption and defective osteoblast production (Yan et al., 2020). A. bidentata alcohol extract increases the proliferative capacity and stimulates the osteogenic differentiation of osteoblasts (Hua and Zhang, 2019). Moreover, it can inhibit osteoclast differentiation (Jiang et al., 2014b). ABB contains saponins, steroids, flavonoids, alkaloids, polysaccharides, and polypeptides. Of these metabolites, ecdysterone, polysaccharides, polypeptides, and saponins are the most characteristic metabolites of ABB (Jiang et al., 2014b).
Previous reviews have discussed the traditional uses, phytochemistry, and pharmacological properties of the genus Achyranthes (Li and Li, 1998; He et al., 2017). Further investigations included high-performance liquid chromatography analysis, processing, extraction conditions, and the biological activity of the saponin metabolites of Achyranthes root (Kiuchi, 2022). This review focuses on the pathogenesis of RA and the effects and molecular mechanisms of ABB and COK for the treatment of RA. A literature search was performed, focusing on research published up to May 2025. In detail, the metabolites contained in ABB and COK were examined using evidence available in the Web of Science, PubMed, China National Knowledge Infrastructure (CNKI), and Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP) (https://tcmspw.com/tcmsp.php) (Ru et al., 2014). Subsequently, the metabolites involved in RA were further filtered. The objective of this review was to improve our understanding of the anti-RA effects of ABB and COK. We first summarized the mechanisms underlying the effects of ABB and COK by focusing on the pathogenesis of the inflammatory process, immunoregulation, fibroblast-like synoviocytes (FLS), angiogenesis, oxidative stress, cartilage degradation, and bone destruction in RA. Data on the pharmacokinetic characteristics of the metabolites of ABB and COK were also summarized. This review attempts to comprehensively summarize the available information on the multiple beneficial effects of the metabolites of ABB and COK on RA, and provide scientific evidence for its traditional use.
2 Effects of ABB and COK on RA
2.1 Extract of ABB and COK
In an adjuvant-induced arthritis (AIA) rat model, treatment with a saponin-rich fraction of A. aspera (50 and 100 mg/kg) for 28 days markedly suppressed paw swelling, reduced the arthritic score, and improved the pain threshold (Kothavade et al., 2015). Zheng et al. isolated and identified ABB saponins in A. aspera root and explored their activity in rats with collagen-induced arthritis (CIA). ABB saponins (150 and 300 mg/kg) dramatically decreased the paw volume of arthritis rats. At the dose of 300 mg/kg, ABB saponins significantly suppressed soft tissue swelling and periarticular bone destruction and improved arthritis symptoms such as synovial joint space narrowing, synovial hyperplasia, fiber tissue hyperplasia, inflammatory cellular infiltration, cartilage erosion, and bony hyperplasia destruction (Zheng et al., 2016). In a rat AIA model, the total saponin content of ABB (30, 60, 120 mg/kg) significantly suppressed paw swelling and redness/inflammation severity in addition to improving synovial hyperplasia, and inflammatory cell infiltration (Fu et al., 2021).
Ecdysteroid-enriched fraction of COK could reduce the arthritis score, paw swelling, and improve histopathological deterioration, and suppress the levels of inflammatory factors, matrix metalloproteinases, and proteins expressed in rat synovial tissue (Huang et al., 2025).
2.2 Metabolites of ABB and COK
A total of 314 metabolites contained in ABB were searched in the literature and TCMSP database, including saponins, steroids, flavonoids, alkaloids, fatty acid, and lignan (Li et al., 2007b; Tao et al., 2019a; Teng et al., 2022; Wang et al., 2022a; Wang et al., 2022b; Yan et al., 2024). Moreover, 185 metabolites contained in COK were searched, including saponins, steroids, flavonoids, alkaloids, fatty acid, and lignan (Yan et al., 2024). Of those, 22 metabolites, mainly derived from the roots of ABB and COK, were related to the treatment of RA, comprising 7 terpenoids, 6 flavonoids, 3 steroids, 2 alkaloids, and 4 others (Table 2) (Chen et al., 2024b). Duan et al. reported that arthritis scores were markedly decreased by higenamine in CIA mice (Duan et al., 2016). Chikusetsusaponin Ⅳa decreased the arthritis index, paw thickness and number of swollen joints in CIA mice (Guo et al., 2021).
TABLE 2
| Metabolites | Source | Model | Dose | Positive control | Biological activities | Mechanisms | References |
|---|---|---|---|---|---|---|---|
| 20-hydroxyecdysone | ABB | LPS-induced RAW 264.7 cells | 12.5 and 25 μM | Indomethacin (2.5 ng/mL) | ↓PGE-2 | unknow | Yoo et al. (2017) |
| β-Sitosterol | ABB, COK | BMDMs CIA mice | 5, 25 and 50 μM 20 and 50 mg/kg | — | ↓iNOS, IL-1β, CD86, MHCII, IgG1 ↑Arg-1, IL-10, CD163, CD206 | unknow | Liu et al. (2019) |
| VEGF-induced HUVECs | 10 and 20 μM | — | ↓VEGFR2, p-VEGFR2 | VEGF pathway | Qian et al. (2021) | ||
| Azelaic acid | ABB | AIA rats | 20, 40, and 80 mg/kg | Piroxicam (10 mg/kg) | ↓TNF-α, IL-17, IL-1β, IL-6, COX-2, PGE-2, 5-LOX, anti-ccp, ESR, CRP, platelets, WBCs, MDA ↑IL-4, IL-10, hemoglobin, RBCs, SOD, CAT, GSH | ↓NF-κB | Sial et al. (2024) |
| Caffeic acid | ABB, COK | RANKL and TNF-α induced RAW264.7 | 0.1, 1, 10 and 100 μg/mL | — | ↓osteoclastogenesis | ↓NFATc1 | Tang et al. (2006) |
| IL-1β induced FLS CIA rats | 1, and 10 μM 30 and 50 mg/kg | — | ↓TNF-α, IL-6, PGE2, MMP-1 | ↓NF-κB pathway | Wang et al. (2017) | ||
| Chikusetsusaponin IVa | ABB, COK | LPS induced THP-1 cells | 50, 100 and 200 μg/mL | — | ↓TNF-α, IL-1β, IL-6, COX-2, iNOS | ↓MAPK, NF-κB pathway | Wang et al. (2015) |
| LPS-induced RAW264.7 cells | 6.25, 12.5 and 25 μM | — | ↓TNF-α, IL-1β, iNOS, NO | ↓miR-155, NF-κB ↑GSK-3β | Xin et al. (2020) | ||
| CIA mice | 50 and 100 mg/kg | Dexamethasone (0.2 mg/kg) | ↓TNF-α, IL-1β, IL-6, IFN-γ | ↓JAK1/2/STAT3 | Guo et al. (2021) | ||
| LPS-induced RAW264.7 cells | 3.125, 6.25, 12.5 μg/mL | — | ↓TNF-α, IL-1β, IL-6, IL-10, COX-2, iNOS, NO, PGE-2 | ↓MAPK pathway | Xu et al. (2021) | ||
| Chikusetsusaponin V | ABB, COK | LPS induced RAW264.7 cells | 0.1, 1, 10, 40 μM | — | ↓NO, iNOS, TNF-α, IL-1β, CD14, TLR4 | ↓MAPK (p-ERK, p-JNK) pathway, NF-κB pathway | Wang et al. (2014) |
| Cichoric Acid | ABB | CIA rats | 8, 16, and 32 mg/kg | Tripterygium glycosides table (10 mg/kg) | ↓TNF-α, IL-1β, PGE-2, COX-2 | ↓p-NF-κB | Jiang et al. (2014a) |
| Coptisine | ABB | FLS | 5, 10, 20 μM | — | ↓proliferation, migration, and invasion of FLS | ↓PSAT1, MAPK pathway | Xu et al. (2024) |
| Higenamine | COK | CIA mice | 10 mg/kg | — | ↓TNF-α, IL-1β, MDA, caspase-3/9 ↑GSH | ↑Nrf2/HO-1 pathway | Duan et al. (2016) |
| Hyperoside | ABB | LPS induced FLS CIA mice | 10, 50, 100 μM 25, 50 mg/kg | — | ↓TNF-α, IL-6, IL-1, MMP-9 | ↓NF-κB pathway | Jin et al. (2016) |
| Kaempferitrin | COK | MH7A cells CIA mice | 5, 10 and 20 μM 10 and 20 mg/kg | — | ↓TNF-α, IL-6, IL-1β, MMP-1, MMP-3 | ↓NF-κB, Akt/mTOR pathway | Wang and Zhao (2019) |
| Kaempferol | ABB | IL-1β induced FLS | 100 µM | — | ↓MMP-1, MMP-3, COX-2, PGE2 | ↓NF-κB, MAPK pathway | Yoon et al. (2013) |
| bone marrow cells | 100 µM | — | ↓TRAP | ↓c-Fos, NFATc1, p-ERK, p-JNK, p-p38 | Lee et al. (2014) | ||
| CIA rats Treg cells | 100 mg/kg 50 μM | — | ↑FOXP3, CTLA4, IL-10 | ↓FOXP3 phosphorylation | Lin et al. (2015) | ||
| CIA mice FLS | 2 mg/kg 2, 10 and 25 μM | — | ↓TNF-α, IL-17, IL-21, TRAP | bFGF/FGFR3/RSK2 pathway | Lee et al. (2018) | ||
| CIA mice TNF-α induced FLS | 50, 100, 200 mg/kg 10, 20 and 40 μM | — | ↓MMP-1, MMP-3, MMP-9, MMP-13 | ↓MAPK pathway | Pan et al. (2018) | ||
| CIA mice | 200 mg/kg | Leflunomide (5 mg/kg) | IL-6, TNF-α, IL-1β, IFN-γ, IgG | ↓gut microbiota (Lachnospiraceae) ↑gut microbiota (Bacteroidales_S24-7_group, Prevotellaceae, Erysipelotrichaceae, Staphylococcaceae, Alcaligenaceae) | Aa et al. (2020) | ||
| Maslinic acid | ABB | Collagen antibody-induced arthritis mice | 200 mg/kg | — | ↓TNF-α, IL-1β | ↓Toll-like receptor signaling, leukotrienes through the glucocorticoid receptor | Shimazu et al. (2019) |
| Momordin Ib | ABB | LPS-induced RAW264.7 cells | 11.28 ± 0.55 μM | — | ↓NO | Unknow | Huang et al. (2021) |
| Momordin Ic | ABB, COK | LPS-induced RAW264.7 cells | 6.25, 12.5 and 25 μM | — | ↓TNF-α, IL-6, PGE-2 | Unknow | Yoo et al. (2017) |
| Nobiletin | ABB, COK | CIA mice IL-1β induced FLS | 15, 30, and 60 mg/kg 16, 32, and 64 μM | — | ↓ADAMTS-4, ADAMTS-5 | Unknow | Imada et al. (2008) |
| CIA rats | 100 and 400 mg/kg | — | ↓TNF-α, IL-6, IL-1β, MCP-1 | ↓p38/NF-κB pathway | Yang et al. (2017) | ||
| IL-21 induced MH7A cells | 25 and 50 μM | — | ↓TNF-α, IL-6, HMGB1, MMP-3, MMP-13, 4-HNE | ↓JAK1/STAT3 pathway | Liu et al. (2020) | ||
| MG-63 cells | 10 and 20 μg/mL | — | ↑BMP-2, COL-I, ALP, OCN, RUNX2, COL1A1 | ↑BMP-2/RUNX2 pathway | Pang et al. (2021) | ||
| Oleanolic acid | ABB, COK | RANKL-induced RAW264.7 cells | 2.5, 5 and 10 μM | Estradiol (1 μM) | ↓TRAP, MMP-9, cathepsin K | ↓RANK ↑ERα/miR-503 pathway | Xie et al. (2019) |
| p-Coumaric acid | ABB, COK | AIA rats | 100 mg/kg | Celecoxib (5 mg/kg) | ↓TNF-α, IL-1β, IL-6, IL-17, MCP-1, RANKL, TRAP, iNOS, COX-2 ↑OPG | ↓NF-κB, MAPK (JNK, p-JNK, ERK1/2) pathway | Neog et al. (2017) |
| Rhoifolin | ABB, COK | AIA rats | 10 and 20 mg/kg | Indomethacin (10 mg/kg) | ↓TNF-α, IL-1β, IL-6, MDA ↑GSH, GSH-Px, SOD | ↓NF-κB pathway | Peng et al. (2020) |
| Stigmasterol | ABB | CIA rats | 200 mg/kg | MTX (0.25 mg/kg) | ↓TNF-α, IL-6, IL-1β, iNOS ↑IL-10 | ↓NF-κB p65, p38MAPK | Khan et al., 2020 |
| CIA rats | 50, 100, and 200 mg/kg | Indomethacin (1.0 mg/kg) | ↓IL-6, IL-1β, RANKL, ACP5, Cathepsin K | Unkown | Xie et al. (2023) | ||
| Ursolic acid | ABB | AIA mice | 10, 20, 40, 80 and 160 mg/kg | Prednisolone (5 mg/kg) | ↓TNF-α, IL-2, IFN-γ | ↓Th1 cells ↑Th2 cells | Ahmad et al. (2006) |
| CIA mice | 150 mg/kg | — | ↓TNF-α, IL-1β, IL-6, IL-21, CII-specific IgG | ↓Th17 and B cell differentiation | Baek et al. (2014) | ||
| FLS | 10 μM | — | ↓Mcl-1 | ↑SP1/Noxa | Kim et al. (2018) | ||
| Wogonin | ABB | LPS-induced HUVECs | 1,10 and 100 μM | Thalidomide (30 μg/mL) | ↓VEGF, VEGFR-2, IL-6 | Unkown | Lin et al. (2006) |
| CIA mice MH7A cells | 40 mg/kg 10,20 and 40 μM | MTX (1 mg/kg) MTX (1 μM) | ↓TNF-α, IL-1β, IL-6, MMP-3, MMP-9, α-SMA ↑IL-10, E-Cad | ↓PI3K/AKT/NF-κB | Yang et al. (2024) |
Effects and mechanism of major metabolites of ABB and COK in the treatment of RA.
3 Mechanisms underlying the effects of ABB and COK on RA
3.1 Modulation of the inflammatory process
3.1.1 Effects on pro-inflammatory cytokines
It is well established that increased levels of pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-6, as well as the imbalance of anti-inflammatory cytokines, such as TGF-β, IL-4, IL-10, and IL-13, lead to the development of RA (Cutolo et al., 2022).
TNF-α can induce the production of other inflammatory cytokines, attracting leukocytes and constructing a synovial inflammatory environment. The synovial inflammatory environment activates macrophages to produce additional pro-inflammatory cytokines, such as IL-6 and IL-1β, which increase synovial inflammation by recruiting and activating other innate immune cells (Kikyo, 2023). Moreover, pro-inflammatory cytokines initiate and maintain the production of further degradative enzymes and prostaglandins, promoting cartilage degradation, bone resorption, and osteoclastogenesis (Markovics et al., 2021). In addition, IL-17 activates multiple downstream signaling cascades that increase the levels of several inflammatory cytokines and chemokines (Adamopoulos et al., 2010). Furthermore, IL-17 enhances osteoblast-mediated bone resorption by promoting the activity of receptor activator of nuclear factor-kappa B ligand (RANKL), macrophage colony-stimulating factor (M-CSF), and prostaglandin E2 (PGE2), thereby increasing cathepsin K (CTSK) and MMP expression (Zhang F. et al., 2011; Ganesan and Rasool, 2017).
In vivo studies showed that 20-hydroxyecdysone (Sun et al., 2017), stigmasterol (Khan et al., 2020), azelaic acid (Sial et al., 2024), ursolic acid (Baek et al., 2014), higenamine (Duan et al., 2016), cichoric acid (Jiang et al., 2014a), p-Coumaric acid (Neog et al., 2017), maslinic acid (Shimazu et al., 2019), rhoifolin (Peng et al., 2020), nobiletin (Yang et al., 2017), kaempferitrin (Wang and Zhao, 2019), and kaempferol (Aa et al., 2020) reduced the production of IL-6, IL-1β, TNF-α, IL-21 and IL-17 (Table 2).
Mechanistically, the primary signaling pathways involved in RA include Janus kinase (JAK), mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K), and nuclear factor kappa-B (NF-κB) (Ding et al., 2023). Chikusetsusaponin IVa (Wang et al., 2015), chikusetsusaponin V (Wang et al., 2014), momordin Ic (Zheng et al., 2020), 20-hydroxyecdysone (Sun et al., 2017), stigmasterol (Khan et al., 2020), wogonin (Yang et al., 2024), caffeic acid (Wang et al., 2017), cichoric acid (Jiang et al., 2014a), p-Coumaric acid (Neog et al., 2017), rhoifolin (Peng et al., 2020), nobiletin (Yang et al., 2017), kaempferitrin (Wang and Zhao, 2019), hyperoside (Jin et al., 2016) suppressed the secretion of IL-1β, IL-6, IL-8, IL-17, and TNF-α via inhibiting NF-κB activation (Figure 1). Chikusetsusaponin IVa (Wang et al., 2015; Xu et al., 2021), chikusetsusaponin V (Xu et al., 2022), stigmasterol (Khan et al., 2020), caffeic acid (Wang et al., 2017), p-Coumaric acid (Neog et al., 2017), nobiletin (Yang et al., 2017) inhibited the production of pro-inflammatory cytokines by down-regulating the MAPK pathway (Figure 1). Moreover, wogonin and higenamine decreased the expression of TNF-α, IL-1β, and IL-6 via the PI3K/protein kinase B (PI3K/AKT) pathway (Duan et al., 2016; Yang et al., 2024). Chikusetsusaponin IVa could effectively and stably bind to IL-1β and interferon-gamma (IFN-γ) and inhibit the JAK/STAT signaling pathway (Guo et al., 2021) (Figure 1).
FIGURE 1
3.1.2 Effects on anti-inflammatory cytokines
IL-10 can downregulate the expression of IL-1β, IL-6 and TNF-α, and reduce osteoclast formation by directly acting on osteoclast precursors (Kitaura et al., 2020). It was previously reported that β-sitosterol, azelaic acid, wogonin, and stigmasterol increased the expression of IL-10 (Liu et al., 2019; Khan et al., 2020; Sial et al., 2024; Yang et al., 2024). The mechanisms underlying these effects may be related to suppression of the MAPK, NF-κB, and PI3K/AKT pathways (Khan et al., 2020; Yang et al., 2024).
IL-4 exerted anti-inflammatory, anti-angiogenic, and bone-protective effects via suppressing pro-inflammatory cytokines, vascular endothelial growth factor (VEGF), osteoclast activation, and bone-resorbing cytokines (Iwaszko et al., 2021). In addition, production of IL-4 was increased by azelaic acid (Sial et al., 2024) (Table 2).
3.1.3 Effects on nitric oxide (NO) and inducible nitric oxide synthase (iNOS)
NO is a significant inflammatory mediator overproduced in serum and synovial fluid of patients with RA, showing a significant correlation with disease activity (Farrell et al., 1992; Ali et al., 2014). Diverse cytokines including TNF-α and IL-6 increased the secretion of iNOS, subsequently promoting the production of NO by a broad spectrum of cells (e.g., macrophages, neutrophils, osteoclasts, osteoblasts, and FLS) into inflamed joints (Spiller et al., 2019; Huang et al., 2023). NO increased the production of inflammatory mediators via regulating the toll-like receptor 4/NF-κB (TLR4/NF-κB) pathway (Huang et al., 2023). Moreover, NO promoted the imbalance of T helper 17/regulatory T (Th17/Treg) cells, Th1/Th2 cells, and bone resorption/formation (Nagy et al., 2010; Spiller et al., 2019; Huang et al., 2023).
Chikusetsusaponin IVa (Wang et al., 2015; Xin et al., 2020), chikusetsusaponin V (Wang et al., 2014), momordin Ib (Huang et al., 2021), 20-hydroxyecdysone (Sun et al., 2017), β-Sitosterol (Liu et al., 2019), stigmasterol (Khan et al., 2020), ursolic acid (Baek et al., 2014), cichoric acid (Jiang L. et al., 2014), p-Coumaric acid (Neog et al., 2017), maslinic acid (Shimazu et al., 2019), nobiletin (Yang et al., 2017), and kaempferol (Aa et al., 2020) decreased the expression of iNOS and NO (Table 2).
3.1.4 Effects on PGE2 and cyclooxygenase-2 (COX-2)
Apart from the above mechanisms, PGE2 formed by COX is a key inflammatory mediator in RA (Park et al., 2006). The production of PGE2 and COX-2 was increased by pro-inflammatory cytokines (e.g., TNF-α and IL-1β) and decreased by anti-inflammatory cytokines (e.g., IL-4, IL-10, and IL-13) (Martel-Pelletier et al., 2003). Evidence has shown that PGE2 is related to inflammation, angiogenesis and bone destruction by increasing the expression of IL-6 (Inoue et al., 2002), VEGF (Ben-Av et al., 1995), and MMP-1 (Kunisch et al., 2009).
Chikusetsusaponin IVa (Wang et al., 2015), chikusetsusaponin V (Kim et al., 2015), momordin Ic (Yoo et al., 2017), stigmasterol (Khan et al., 2020), azelaic acid (Sial et al., 2024), caffeic acid (Wang et al., 2017), cichoric acid (Jiang et al., 2014a), p-Coumaric acid (Neog et al., 2017), maslinic acid (Shimazu et al., 2019), nobiletin (Yang et al., 2017), kaempferol (Aa et al., 2020), and 20-Hydroxyecdysone (Yoo et al., 2017) suppressed the production of COX-2 and PGE2 (Table 2).
3.2 Regulation of immunity
3.2.1 Effects on T cells
Through the induction of diverse cytokines, CD4+ T cells differentiate towards T cell subsets, including Th17, Treg, Th1, and Th2 (Gomez-Bris et al., 2023). Studies demonstrated that the imbalance of Th17/Treg and Th1/Th2 cells was closely related to inflammation and bone destruction in RA (Wang et al., 2024b; Yang and Zhu, 2024). Ursolic acid and kaempferol regulated the balance of Treg and Th17 cells by decreasing Th17 cells and increasing Treg cells (Baek et al., 2014; Lin et al., 2015; Lee et al., 2018). Ursolic acid decreased the cytokines of Th1 cells (Ahmad et al., 2006). Of note, ursolic acid increased the cytokines of Th2 cells (Ahmad et al., 2006) (Table 2).
3.2.2 Effects on B cells
The functions of B cells include antigen presentation, cytokine secretion and autoantibody production, which are closely associated with the pathogenesis of RA (Wu et al., 2021a; Jang et al., 2022). In vitro studies showed that ursolic acid suppressed B cell activation and differentiation (Baek et al., 2014). Aa et al. reported that kaempferol decreased anti-collagen type II IgG levels in CIA mice (Aa et al., 2020). Liu et al. reported that β-sitosterol suppressed the levels of IgG and IgG1 antibodies, but did not affect those of IgG2c (Liu et al., 2019) (Table 2).
3.2.3 Effects on macrophages
Macrophages play a crucial role in RA pathogenesis via polarization into M1 and M2 types (Yang et al., 2020). M1 macrophages produce pro-inflammatory cytokines (e.g., TNF-α, IL-6, IL-1β, IL-8, IL-12, and IL-23), while M2 macrophages produce anti-inflammatory cytokines (e.g., IL-10, IL-4, IL-13, and TGF-β) (Zheng et al., 2024). The proportions of M1 and M2 macrophages are imbalanced in the synovial fluid (Zhu et al., 2015), synovium (Ambarus et al., 2012) and peripheral blood (Tardito et al., 2019) in patients with RA. By modulating macrophage polarization, β-sitosterol inhibited the expression of iNOS, IL-1β, CD86, and major histocompatibility complex class II (MHCII), whereas it increased that of arginase-1 (ARG1), IL-10, CD163, and CD206 (Liu et al., 2019) (Table 2).
3.3 Effects on FLS
Proliferation of synovial tissue, an important feature of RA, is mainly attributed to hyperproliferation and decreased apoptosis of FLS (Tu et al., 2018). Coptisine (Xu et al., 2024), wogonin (Yang et al., 2024), kaempferitrin (Wang and Zhao, 2019), hyperoside (Jin et al., 2016), and kaempferol (Lee et al., 2018; Pan et al., 2018) suppressed the proliferation, migration, and invasion of FLS. Furthermore, caffeic acid (Wang et al., 2017), ursolic acid (Kim et al., 2018), and kaempferitrin (Wang and Zhao, 2019) induced apoptosis of FLS.
FLS have pro-inflammatory, angiogenic, and bone-destructive effects via overproduction of pro-inflammatory cytokines, chemokines, pro-angiogenic factors, collagenases, aggrecanases, cathepsins, and RANKL (Nygaard and Firestein, 2020; Wu et al., 2021b). It was reported that wogonin (Yang et al., 2024), caffeic acid (Wang et al., 2017), and hyperoside (Jin et al., 2016) suppressed the expression of TNF-α, IL-1β, IL-6, IL-8, IL-17 and IL-18 produced by FLS (Table 2).
3.4 Inhibition of angiogenesis
In RA, angiogenesis can be induced by inflammation, immune imbalance, and hypoxia, promoting synovial hyperplasia, pannus formation, and bone destruction (Wang et al., 2021). Angiogenesis is tightly regulated by VEGF and its receptors, which have been extensively studied (Khodadust et al., 2022). β-sitosterol and wogonin suppressed rheumatoid synovial angiogenesis via down-regulating vascular endothelial growth factor receptor 2 (VEGFR2) and phospho-VEGFR2 expression (Lin et al., 2006; Qian et al., 2021).
3.5 Inhibition of oxidative stress
In the arthritic joint, neutrophils can drive inflammation by releasing a variety of potentially harmful peptides, enzymes, and toxic oxygen metabolites (Cecchi et al., 2018). Myeloperoxidase, an abundant peroxidase in neutrophils, is found in the plasma and synovium of patients with RA (Fernandes et al., 2012; Odobasic et al., 2014). Moreover, increased oxidative stress decreases the levels of superoxide dismutase, catalase, glutathione, glutathione S-transferase, glutathione reductase, and glutathione peroxidase (Tang et al., 2022). The decrease in antioxidant defense is accompanied by a concurrent increase in the levels of ROS and NO (Wójcik et al., 2021). High levels of malondialdehyde indicate increased lipid peroxidation, which can activate signaling pathways involved in the inflammatory processes of RA (Tsikas and Mikuteit, 2022). Azelaic acid (Sial et al., 2024), 20-hydroxyecdysone (Sun et al., 2017), higenamine (Duan et al., 2016), and rhoifolin (Peng et al., 2020) can inhibit the decrease in superoxide dismutase, catalase, glutathione, glutathione peroxidase activity, and the increase in malondialdehyde content (Table 2).
3.6 Inhibition of cartilage and bone destruction
Under normal physiologic circumstances, bone remodeling is continuously conducted by osteoblasts and osteoclasts, which are responsible for bone resorption and bone formation, respectively. However, under arthritic conditions, the excessive activation of osteoclasts is associated with suppressed osteoblast development.
3.6.1 Effects on osteoclasts
In RA, osteoclasts play a crucial role in bone resorption. Osteoclasts are formed by the fusion of osteoclast precursors, derived from monocyte/macrophage precursors or hematopoietic stem cells. TNF-α can regulate bone resorption by increasing RANKL and M-CSF expression in osteoblasts and stromal cells (Marahleh et al., 2019). The binding of M-CSF and colony-stimulating factor 1 receptor is essential for the survival, proliferation, differentiation and function of myeloid cells, including osteoclasts and monocytes/macrophages (Mun et al., 2020). Inhibition of osteoclastogenesis, osteoclast differentiation, and osteoclast function is a major target in the treatment of RA. Chikusetsusaponin IVa, momordin Ib and momordin IIa inhibited the formation of 1α,25(OH)2D3-induced osteoclast-like multinucleated cells in a co-culture system without irreversible toxicity (Li et al., 2005). Stigmasterol inhibited the expression of osteoclast-specific genes including cathepsin K, MMP-9 and tartrate-resistant acid phosphatase (TRAP) (Xie et al., 2023) (Table 2).
Upregulation of osteoclast activity in the development of RA is controlled by osteocytes through the osteoprotegerin/RANKL/RANK (OPG/RANKL/RANK) system (Zhang and Wen, 2021). RANKL binds to RANK on mononuclear osteoclast precursors. Subsequently, it recruits TRAF6, TGF-β activated kinase 1 binding protein 1 (TAB1), and TAB2 to sequentially activate TAK1 and promotes the activation of MAPKs, NF-κB and c-Fos. Finally, it induces the nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), which is a crucial transcription factor of osteoclast differentiation (Maeda et al., 2022; Yang and Zhu, 2024). OPG, a decoy receptor of RANKL, blocks the RANKL-RANK interaction to inhibit osteoclast formation (Yao et al., 2021). Oleanolic acid significantly suppressed osteoclast differentiation and bone resorption via the estrogen receptor alpha/miR-503/RANK (ERα/miR-503/RANK) signaling pathway (Xie et al., 2019). Caffeic acid exerted an inhibitory effect on osteoclastogenesis by inhibiting the expression of NFATc1 (Tang et al., 2006). p-Coumaric acid inhibited osteoclastogenesis via up-regulating OPG expression and down-regulating RANKL, NFATc1 and c-Fos expression (Neog et al., 2017). Additionally, kaempferol attenuated osteoclast differentiation by suppressing the MAPK/c-fos/NFATc1 signaling pathway (Lee et al., 2014) (Table 2).
3.6.2 Effects on osteoblasts
Osteoblasts are derived from mesenchymal stem cells in the bone marrow. These cells differentiate into osteoblasts, adipocytes or chondrocytes. Their differentiation into the osteogenic lineages is tightly controlled by molecular factors, such as bone morphogenic protein (BMP) and Wnt pathways (Datta et al., 2008; Zhang et al., 2011b). The canonical Wnt signalling pathway affects osteoblast proliferation and differentiation. MAPK is also thought to mediate the activation of several gene products related to bone formation, such as alkaline phosphatase (ALP) and transcription factors, including runt-related transcription factor 2 (RUNX2), osterix (OSX), and BMP2 (Hua and Zhang, 2019). Numerous reports over the last 2 decades showed that osteoblast differentiation also relies on miRNAs, and several miRNAs target the Wnt and BMP pathways, thereby modulating osteoblast differentiation (Ponzetti and Rucci, 2021). ALP activity is the gold standard for evaluating osteoblast differentiation. Chikusetsusaponin IVa was positively correlated with ALP activation, while chikusetsusaponin V and chikusetsusaponin IV were negatively correlated with ALP (Tao et al., 2019a). Nobiletin augmented the expression of type I collagen (COL-I), ALP, osteocalcin (OCN), and collagen type I alpha 1 chain (COL1A1) via promoting the BMP2/RUNX2 pathway (Pang et al., 2021) (Table 2).
3.6.3 Effects on MMPs
RA is characterized by the loss of cartilage and bone matrix integrity (Komatsu and Takayanagi, 2022). Reversing the anabolic/catabolic imbalance of matrix remodeling is crucial to maintaining cartilage and bone integrity (Deng et al., 2022). Extracellular matrix (ECM) destruction occurs in the RA joint. The ECM primarily consists of type II collagen and proteoglycans. Matrix-degrading enzymes, such as MMPs and the A disintegrin and metalloproteinase with thrombospondin motif (ADAMTS) family degrade the ECM (Bian et al., 2023). ECM breakdown products (e.g., such as fibronectin fragments, tenascin C, and hyaluronic acid) can induce the production of pro-inflammatory cytokines, as well as MMP-3, MMP-9, and MMP-13, accelerating the breakdown of cartilage and bone. Inflammation can also promote the expression of MMPs, ADAMTS, and ROS, further promoting cartilage and bone destruction. Nobiletin (Imada et al., 2008; Liu et al., 2020), kaempferitrin (Wang and Zhao, 2019), and kaempferol (Yoon et al., 2013; Pan et al., 2018) significantly suppressed the expression of MMPs and ADAMTS family (Table 2).
4 Pharmacokinetic characteristics
Currently, there is limited number of pharmacokinetic studies of ABB extracts. Tao et al. studied the pharmacokinetics of chikusetsusaponin IV, chikusetsusaponin IVa and ginsenoside Ro in rats after oral administration of crude and salt-processed ABB. A double-peak phenomenon was observed for these three saponins. After oral gavage of crude and salt-processed ABB in rats, the highest values of the area under the curve up to the last quantifiable time-point (AUC0-t) and maximum concentration (Cmax) of the three saponins were observed in kidney tissue, followed by liver, spleen, heart, and lung tissues. The concentration of ginsenoside Ro and chikusetsusaponin IVa was higher in the raw extract than the salt-processed ABB. However, the Cmax values of ginsenoside Ro and chikusetsusaponin IVa in rat plasma were lower in the raw group than the salt-processed group. This finding demonstrated that salt-processing resulted in enhanced bioavailability (Tao et al., 2018; Tao et al., 2019b).
Cyasterone, 25-epi-28-epi-cyasterone, precyasterone and capitasterone from COK phytoecdysteroids extract in normal and AIA rats were studied and the results demonstrated that the plasma concentrations of those metabolites were lower in AIA rats than in normal rats at almost all time points. The mechanism of the difference between normal rats and AIA rats with RA requires further research (Wang et al., 2023).
5 Safety assessment of ABB and COK
ABB is a botanical drug, commonly used to treat a variety of diseases. The oral toxicity and genotoxicity of single-dose (500, 1000, and 2000 mg/kg) and 4-week repeated-doses of water extract of ABB were evaluated. The single-dose oral toxicity study showed no mortality or treatment-related body weight changes, with the lethal dose in rats estimated to exceed 2000 mg/kg. The 4-week study on repeated oral doses showed that ARB did not lead to significant changes in body weight, organ weight, food intake, or hematological and serum biochemical parameters across all groups. Meanwhile, ABB did not induce genotoxicity in the chromosomal aberration test and micronucleus test (Hyun et al., 2021).
The mice displayed neurotoxic and gastrointestinal toxic effects after receiving a high dose of water extract of COK. The range of maximum tolerance doses for samples from different origins was between 34.9 and 56.8 g/kg (Huang et al., 2019). The recommended dosage for COK is 5–10 g in the National Medical Products Administration. Therefore, it is crucial to avoid high doses or prolonged use in clinical practice.
6 Discussion
RA is an inflammatory autoimmune disease. Currently drugs not only alleviate pain and swelling but also prevent damage to joint. Despite this, treating up to 20% of RA patients is challenging (de Hair et al., 2018), and these drugs can result in gastrointestinal bleeding and liver toxicity (Lin et al., 2020). TCM is gradually developing into an important complementary medical treatment strategy. ‘Niuxi’ is one of the most commonly utilized TCM treatment options for RA (Cai et al., 2024). Studies have shown that the metabolites contained in ABB and COK can significantly delay the progression of RA. However, some anti-RA effects of these metabolites have mostly remained at the in vitro level, further investigation is necessary to assess the therapeutic impact of metabolites contained in ABB and COK for the treatment of RA.
This review revealed that 22 metabolites contained in ABB and COK, including higenamine and chikusetsusaponin Ⅳa, exhibited anti-RA activity. These metabolites modulate the inflammatory process, regulate immunity, decrease the proliferation, migration, and invasion of FLS, induce apoptosis of FLS, inhibit angiogenesis and oxidative stress, and suppress the destruction of cartilage and bone. Many signaling pathways, such as NF-κB, MAPK, PI3K/AKT, and JAK/STAT, participate in the progression of RA (Table 2; Figure 1). NF-κB, MAPK, PI3K/AKT are important intracellular signaling pathways that play critical roles in the inflammation and bone destruction of RA (Liu et al., 2021a). TNF-α binds to TNFR and RANKL binds to RANK, recruiting TRAF and activating the PI3K/AKT, NF-κB and MAPK pathway (Ma et al., 2018; Shi and Sun, 2018). However, the research on its mechanism is still not in-depth. In the future, genomics, proteomics, and metabolomics and network pharmacology can be used to clarify the mechanism of ABB and COK for the treatment of RA, thereby enhancing its benefits to human health (Zhang et al., 2024; Lu, 2025). Meanwhile, the use of standardized animal models for RA, together with TCM symptom characteristics, is crucial for studying the molecular mechanisms of ABB and COK on RA (Zhou et al., 2023).
The present review indicates that the metabolites contained in ABB and COK may be a great complementary medicine option for RA. Although the mechanisms of metabolites contained in ABB and COK for treating RA were summarized via multiple targets and pathways, there is limited number of studies to explore combination therapy of metabolites from ABB or COK. It is necessary to explore combination therapy of metabolites from ABB or COK on RA in the future.
Chinese medicinal materials from animals, plants, and minerals must be treated properly before being used in decoctions. Such processes greatly influence the content and pharmacological activity of major metabolites (Han et al., 2019; Chen et al., 2020). ABB is generally prepared with yellow rice wine or salt water to enhance actions, such as enriching the kidneys, nourishing the liver, and strengthening the sinews and bones. Salt-processing leads to high levels of β-ecdysterone, 25-S inokosterone, 25-R inokosterone, chikusetsusaponin V, and chikusetsusaponin IVa, which were higher than that those detected in raw and wine-processed ABB (Yang et al., 2018). The levels of ginsenoside Ro and chikusetsusaponin IV were reduced, which could enhance the anti-osteoporotic effects of ABB (Tao et al., 2019a). The processing method has a significant influence on the content of each metabolite.
Previous studies have reported that the plasma concentrations of COK-derived phytoecdysteroids were lower in AIA rats than in normal rats (Wang et al., 2023). Various pathological mechanisms of RA may lead to changes in the absorption of metabolites, which requires further research.
In conclusion, ABB and COK metabolites represent have significant medicinal value and potential in the treatment of RA. Thus far, studies on the anti-RA activity of these metabolites have mostly remained at the in vitro level, and mechanism research is not in-depth enough, clinical research evidence is lacking. Therefore, in-depth mechanism studies and clinical research are warranted to support the clinical application of these metabolites.
Statements
Author contributions
L-BZ: Writing – original draft, Formal Analysis. YY: Writing – original draft. W-WL: Writing – review and editing, Visualization. WZ: Writing – review and editing, Investigation, Formal Analysis. C-YX: Writing – review and editing, Investigation, Formal Analysis. JH: Supervision, Writing – review and editing. YX: Conceptualization, Supervision, Writing – review and editing.
Funding
The author(s) declare that financial support was received for the research and/or publication of this article. This work was supported by grants from the National High Level Hospital Clinical Research Funding (NO. 2022-NHLHCRF-LX-02-02), Excellence & Innovation Initiative of China-Japan Friendship Hospital (NO. ZRZC2025-ZYC02), and Elite Medical Professionals Project of China-Japan Friendship Hospital (NO. ZRJY2023-QM28).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AaL. X.FeiF.QiQ.SunR. B.GuS. H.DiZ. Z.et al (2020). Rebalancing of the gut flora and microbial metabolism is responsible for the anti-arthritis effect of kaempferol. Acta Pharmacol. Sin.41 (1), 73–81. 10.1038/s41401-019-0279-8
2
AdamopoulosI. E.ChaoC. C.GeisslerR.LafaceD.BlumenscheinW.IwakuraY.et al (2010). Interleukin-17A upregulates receptor activator of NF-kappaB on osteoclast precursors. Arthritis Res. Ther.12 (1), R29. 10.1186/ar2936
3
AhmadS. F.KhanB.BaniS.SuriK. A.SattiN. K.QaziG. N. (2006). Amelioration of adjuvant-induced arthritis by ursolic acid through altered Th1/Th2 cytokine production. Pharmacol. Res.53 (3), 233–240. 10.1016/j.phrs.2005.11.005
4
AliA. M.HabeebR. A.El-AziziN. O.KhattabD. A.Abo-ShadyR. A.ElkabarityR. H. (2014). Higher nitric oxide levels are associated with disease activity in Egyptian rheumatoid arthritis patients. Rev. Bras. Reumatol.54 (6), 446–451. 10.1016/j.rbr.2014.07.003
5
AmbarusC. A.NoordenbosT.de HairM. J.TakP. P.BaetenD. L. (2012). Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis. Arthritis Res. Ther.14 (2), R74. 10.1186/ar3796
6
Babiker-MohamedM. H.BhandariS.RanganathanP. (2024). Pharmacogenetics of therapies in rheumatoid arthritis: an update. Best. Pract. Res. Clin. Rheumatol.38, 101974. 10.1016/j.berh.2024.101974
7
BaekS. Y.LeeJ.LeeD. G.ParkM. K.LeeJ.KwokS. K.et al (2014). Ursolic acid ameliorates autoimmune arthritis via suppression of Th17 and B cell differentiation. Acta Pharmacol. Sin.35 (9), 1177–1187. 10.1038/aps.2014.58
8
BaigM.WongL. K.ZiaA. W.WuH. (2024). Development of biomedical hydrogels for rheumatoid arthritis treatment. Asian J. Pharm. Sci.19 (1), 100887. 10.1016/j.ajps.2024.100887
9
Ben-AvP.CroffordL. J.WilderR. L.HlaT. (1995). Induction of vascular endothelial growth factor expression in synovial fibroblasts by prostaglandin E and interleukin-1: a potential mechanism for inflammatory angiogenesis. FEBS Lett.372 (1), 83–87. 10.1016/0014-5793(95)00956-a
10
BianY.XiangZ.WangY.RenQ.ChenG.XiangB.et al (2023). Immunomodulatory roles of metalloproteinases in rheumatoid arthritis. Front. Pharmacol.14, 1285455. 10.3389/fphar.2023.1285455
11
CaiG.Any.YangJ.ZhaoQ.WenH.XieL. (2024). Research on the medication rules for treating rheumatoid arthritis based on data mining from the Chinese medical dictionary. Rheumatism Arthritis13 (09), 7–13.
12
CaoY.GuC.ZhaoF.TangY.CuiX.ShiL.et al (2017). Therapeutic effects of Cyathula officinalis kuan and its active fraction on acute blood stasis rat model and identification constituents by HPLC-QTOF/MS/MS. Pharmacogn. Mag.13 (52), 693–701. 10.4103/pm.pm_560_16
13
CecchiI.Arias de la RosaI.MenegattiE.RoccatelloD.Collantes-EstevezE.Lopez-PedreraC.et al (2018). Neutrophils: novel key players in rheumatoid arthritis. Current and future therapeutic targets. Autoimmun. Rev.17 (11), 1138–1149. 10.1016/j.autrev.2018.06.006
14
ChenL.LiuY.YangH. (2024b). The efficacy and mechanism of sanbi decoction combined with methotrexate and leflunomide in the treatment of rheumatoid arthritis with wind cold dampness syndrome. J. Chin. Med. Mater.47 (03), 756–760. 10.13863/j.issn1001-4454.2024.03.039
15
ChenY. R.NiuY. S.ZhouH. L. (2024a). Achyranthes bidentata blume (amaranthaceae): a review of its botany, traditional uses, phytochemistry, pharmacology, and toxicology. J. Pharm. Pharmacol.76 (8), 930–966. 10.1093/jpp/rgae012
16
ChenZ.YeS. Y.ZhuR. G. (2020). The extraordinary transformation of traditional Chinese medicine: processing with liquid excipients. Pharm. Biol.58 (1), 561–573. 10.1080/13880209.2020.1778740
17
ChinnasamyV.SubramaniyanV.ChandiranS.KayarohanamS.KanniyanD. C.VelagaV.et al (2019). Antiarthritic activity of Achyranthes aspera on formaldehyde - induced arthritis in rats. Open Access Maced. J. Med. Sci.7 (17), 2709–2714. 10.3889/oamjms.2019.559
18
CutoloM.CampitielloR.GotelliE.SoldanoS. (2022). The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis. Front. Immunol.13, 867260. 10.3389/fimmu.2022.867260
19
DattaH. K.NgW. F.WalkerJ. A.TuckS. P.VaranasiS. S. (2008). The cell biology of bone metabolism. J. Clin. Pathol.61 (5), 577–587. 10.1136/jcp.2007.048868
20
de HairMJHJacobsJWGSchoneveldJLMet al (2018). Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford), 57 (7), 1135–44. 10.1093/rheumatology/kex349
21
DengZ.ChenX.LinZ.AlahdalM.WangD.LiuJ.et al (2022). The homeostasis of cartilage matrix remodeling and the regulation of volume-sensitive ion channel. Aging Dis.13 (3), 787–800. 10.14336/ad.2021.1122
22
DingQ.HuW.WangR.YangQ.ZhuM.LiM.et al (2023). Signaling pathways in rheumatoid arthritis: implications for targeted therapy. Signal Transduct. Target Ther.8 (1), 68. 10.1038/s41392-023-01331-9
23
DingX. H.TongJ. L.XuJ. Q.GuanM. C.YingY. R.ZhuR. T. (2021). The effect of celecoxib capsule combined with angelicaepubescentis and loranthi pill on rheumatoid arthritis and levels of interleukin 6 and tumor necrosis factor α in peripheral blood. Chin. J. Health Laboratory Technol.31 (8), 972–974.
24
DuanW.ChenJ.WuY.ZhangY.XuY. (2016). Protective effect of higenamine ameliorates collagen-induced arthritis through heme oxygenase-1 and PI3K/Akt/Nrf-2 signaling pathways. Exp. Ther. Med.12 (5), 3107–3112. 10.3892/etm.2016.3730
25
FangZ. Y.LiH.BaiL. Q.LiY. H. (2019). Effects of yuxuebi tablets combined with methotrexate on Lysholm,VAS and ADL scores and serum levels of IL-1,TNF-alpha and ICMAM-1 in patients with rheumatoid arthritis. China Pharm.22 (11), 2062–2065.
26
FarrellA. J.BlakeD. R.PalmerR. M.MoncadaS. (1992). Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann. Rheum. Dis.51 (11), 1219–1222. 10.1136/ard.51.11.1219
27
FengH.FanJ.LinL.LiuY.ChaiD.YangJ. (2019). Immunomodulatory effects of phosphorylated Radix cyathulae officinalis polysaccharides in immunosuppressed mice. Molecules24 (22), 4150. 10.3390/molecules24224150
28
FernandesR. M.da SilvaN. P.SatoE. I. (2012). Increased myeloperoxidase plasma levels in rheumatoid arthritis. Rheumatol. Int.32 (6), 1605–1609. 10.1007/s00296-011-1810-5
29
FuJ.WuH.WuH.DengR.SunM. (2021). Deciphering the metabolic profile and pharmacological mechanisms of Achyranthes bidentata blume saponins using ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry coupled with network pharmacology-based investigation. J. Ethnopharmacol.274, 114067. 10.1016/j.jep.2021.114067
30
GanesanR.RasoolM. (2017). Interleukin 17 regulates SHP-2 and IL-17RA/STAT-3 dependent Cyr61, IL-23 and GM-CSF expression and RANKL mediated osteoclastogenesis by fibroblast-like synoviocytes in rheumatoid arthritis. Mol. Immunol.91, 134–144. 10.1016/j.molimm.2017.09.003
31
GaoY.ZhangY.LiuX. (2024). Rheumatoid arthritis: pathogenesis and therapeutic advances. MedComm5 (3), e509. 10.1002/mco2.509
32
GaoZ.LuY.HalmuratU.JingJ.XuD. (2013). Study of osteoporosis treatment principles used historically by ancient physicians in Chinese medicine. Chin. J. Integr. Med.19 (11), 862–868. 10.1007/s11655-013-1328-z
33
Gomez-BrisR.SaezA.Herrero-FernandezB.RiusC.Sanchez-MartinezH.Gonzalez-GranadoJ. M. (2023). CD4 T-Cell subsets and the pathophysiology of inflammatory bowel disease. Int. J. Mol. Sci.24 (3), 2696. 10.3390/ijms24032696
34
GuoX.JiJ.ZhangJ.HouX.FuX.LuoY.et al (2021). Anti-inflammatory and osteoprotective effects of chikusetsusaponin ⅣA on rheumatoid arthritis via the JAK/STAT signaling pathway. Phytomedicine93, 153801. 10.1016/j.phymed.2021.153801
35
HanL.WangR.ZhangX.YuX.ZhouL.SongT.et al (2019). Advances in processing and quality control of traditional Chinese medicine coptidis rhizoma (huanglian): a review. J. AOAC Int.102 (3), 699–707. 10.5740/jaoacint.18-0303
36
HanX.ShenS.LiuT.DuX.CaoX.FengH.et al (2015). Characterization and antioxidant activities of the polysaccharides from Radix cyathulae officinalis kuan. Int. J. Biol. Macromol.72, 544–552. 10.1016/j.ijbiomac.2014.09.007
37
HeX.WangX.FangJ.ChangY.NingN.GuoH.et al (2017). The genus achyranthes: a review on traditional uses, phytochemistry, and pharmacological activities. J. Ethnopharmacol.203, 260–278. 10.1016/j.jep.2017.03.035
38
HuaS.ZhangX. (2019). Effects of Achyranthes bidentata alcohol on proliferation capacity of osteoblasts and miRNA in Runx2. Exp. Ther. Med.18 (3), 1545–1550. 10.3892/etm.2019.7723
39
HuangH. T.LinY. C.ZhangL. J.LiawC. C.ChenH. Y.HsuehM. T.et al (2021). Anti-inflammatory and anti-proliferative oleanane-type triterpene glycosides from the Vine of Momordica cochinchinensis. Nat. Prod. Res.35 (16), 2707–2714. 10.1080/14786419.2019.1666383
40
HuangJ. B.ChenZ. R.YangS. L.HongF. F. (2023). Nitric oxide synthases in rheumatoid arthritis. Molecules28 (11), 4414. 10.3390/molecules28114414
41
HuangY.WangS.LiuL.PengW.WangJ.SongY.et al (2019). Review of traditional uses, botany, chemistry, pharmacology, pharmacokinetics, and toxicology of Radix cyathulae. Chin. Med.14, 17. 10.1186/s13020-019-0237-x
42
HuangY. H.QiuL.PengY.CaiR.XiaoQ. Q.LiM. C.et al (2025). Ecdysteroid-enriched fraction of Cyathula officinalis suppresses synovial proliferation and inflammation to ameliorate RA by inhibiting the AKT/PI3K/mTOR signaling pathway. J. Asian Nat. Prod. Res., 1–23. 10.1080/10286020.2025.2492357
43
HyunS. W.LeeT. G.SongS. J.KimC. S. (2021). Evaluation of oral toxicity and genotoxicity of achyranthis radix extract. J. Ethnopharmacol.274, 113944. 10.1016/j.jep.2021.113944
44
ImadaK.LinN.LiuC.LuA.ChenW.YanoM.et al (2008). Nobiletin, a citrus polymethoxy flavonoid, suppresses gene expression and production of aggrecanases-1 and -2 in collagen-induced arthritic mice. Biochem. Biophys. Res. Commun.373 (2), 181–185. 10.1016/j.bbrc.2008.05.171
45
InoueH.TakamoriM.ShimoyamaY.IshibashiH.YamamotoS.KoshiharaY. (2002). Regulation by PGE2 of the production of interleukin-6, macrophage colony stimulating factor, and vascular endothelial growth factor in human synovial fibroblasts. Br. J. Pharmacol.136 (2), 287–295. 10.1038/sj.bjp.0704705
46
IwaszkoM.BiałyS.Bogunia-KubikK. (2021). Significance of interleukin (IL)-4 and IL-13 in inflammatory arthritis. Cells10 (11), 3000. 10.3390/cells10113000
47
JangS.KwonE. J.LeeJ. J. (2022). Rheumatoid arthritis: pathogenic roles of diverse immune cells. Int. J. Mol. Sci.23 (2), 905. 10.3390/ijms23020905
48
JiangL.LiW.WangY.ZhangX.YuD.YinY.et al (2014a). Effects of cichoric acid extract from Echinacea purpurea on collagen-induced arthritis in rats. Am. J. Chin. Med.42 (3), 679–692. 10.1142/s0192415x1450044x
49
JiangY.ZhangY.ChenW.LiuC.LiX.SunD.et al (2014b). Achyranthes bidentata extract exerts osteoprotective effects on steroid-induced osteonecrosis of the femoral head in rats by regulating RANKL/RANK/OPG signaling. J. Transl. Med.12, 334. 10.1186/s12967-014-0334-7
50
JinX. N.YanE. Z.WangH. M.SuiH. J.LiuZ.GaoW.et al (2016). Hyperoside exerts anti-inflammatory and anti-arthritic effects in LPS-Stimulated human fibroblast-like synoviocytes in vitro and in mice with collagen-induced arthritis. Acta Pharmacol. Sin.37 (5), 674–686. 10.1038/aps.2016.7
51
KhanM. A.SarwarA.RahatR.AhmedR. S.UmarS. (2020). Stigmasterol protects rats from collagen induced arthritis by inhibiting proinflammatory cytokines. Int. Immunopharmacol.85, 106642. 10.1016/j.intimp.2020.106642
52
KhodadustF.EzdoglianA.SteinzM. M.van BeijnumJ. R.ZwezerijnenG. J. C.JansenG.et al (2022). Systematic review: targeted molecular imaging of angiogenesis and its mediators in rheumatoid arthritis. Int. J. Mol. Sci.23 (13), 7071. 10.3390/ijms23137071
53
KikyoN. (2023). Circadian regulation of macrophages and osteoclasts in rheumatoid arthritis. Int. J. Mol. Sci.24 (15), 12307. 10.3390/ijms241512307
54
KimE. Y.SudiniK.SinghA. K.HaqueM.LeamanD.KhuderS.et al (2018). Ursolic acid facilitates apoptosis in rheumatoid arthritis synovial fibroblasts by inducing SP1-mediated noxa expression and proteasomal degradation of Mcl-1. Faseb J.32 (11), fj201800425R. 10.1096/fj.201800425R
55
KimS.OhM. H.KimB. S.KimW. I.ChoH. S.ParkB. Y.et al (2015). Upregulation of heme oxygenase-1 by ginsenoside Ro attenuates lipopolysaccharide-induced inflammation in macrophage cells. J. Ginseng Res.39 (4), 365–370. 10.1016/j.jgr.2015.03.008
56
KitauraH.MarahlehA.OhoriF.NoguchiT.ShenW. R.QiJ.et al (2020). Osteocyte-related cytokines regulate osteoclast formation and bone resorption. Int. J. Mol. Sci.21 (14), 5169. 10.3390/ijms21145169
57
KiuchiF. (2022). Saponin constituents of achyranthes root. J. Nat. Med.76 (2), 343–351. 10.1007/s11418-021-01591-1
58
KomatsuN.TakayanagiH. (2022). Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. Nat. Rev. Rheumatol.18 (7), 415–429. 10.1038/s41584-022-00793-5
59
KothavadeP. S.BulaniV. D.NagmotiD. M.DeshpandeP. S.GawaliN. B.JuvekarA. R. (2015). Therapeutic effect of saponin rich fraction of Achyranthes aspera linn. On adjuvant-induced arthritis in sprague-dawley rats. Autoimmune Dis.2015, 943645. 10.1155/2015/943645
60
KunischE.JansenA.KojimaF.LöfflerI.KapoorM.KawaiS.et al (2009). Prostaglandin E2 differentially modulates proinflammatory/prodestructive effects of TNF-Alpha on synovial fibroblasts via specific E prostanoid receptors/cAMP. J. Immunol.183 (2), 1328–1336. 10.4049/jimmunol.0900801
61
LeeC. J.MoonS. J.JeongJ. H.LeeS.LeeM. H.YooS. M.et al (2018). Kaempferol targeting on the fibroblast growth factor receptor 3-ribosomal S6 kinase 2 signaling axis prevents the development of rheumatoid arthritis. Cell Death Dis.9 (3), 401. 10.1038/s41419-018-0433-0
62
LeeW. S.LeeE. G.SungM. S.YooW. H. (2014). Kaempferol inhibits IL-1β-stimulated, RANKL-Mediated osteoclastogenesis via downregulation of MAPKs, c-Fos, and NFATc1. Inflammation37 (4), 1221–1230. 10.1007/s10753-014-9849-6
63
LiE. K.TamL. S.WongC. K.LiW. C.LamC. W.Wachtel-GalorS.et al (2007a). Safety and efficacy of Ganoderma lucidum (Lingzhi) and san miao san supplementation in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled pilot trial. Arthritis Rheum.57 (7), 1143–1150. 10.1002/art.22994
64
LiJ.QiH.QiL. W.YiL.LiP. (2007b). Simultaneous determination of main phytoecdysones and triterpenoids in Radix achyranthis bidentatae by high-performance liquid chromatography with diode array-evaporative light scattering detectors and mass spectrometry. Anal. Chim. Acta596 (2), 264–272. 10.1016/j.aca.2007.05.016
65
LiJ. X.HareyamaT.TezukaY.ZhangY.MiyaharaT.KadotaS. (2005). Five new oleanolic acid glycosides from Achyranthes bidentata with inhibitory activity on osteoclast formation. Planta Med.71 (7), 673–679. 10.1055/s-2005-871275
66
LiT.ZhengB. L.YeM. X.HuangY. H.ChenJ. L.LiangJ. L. (2020). The therapeutic effect of tongbi capsule on rheumatoid arthritis and its effect on microcirculation and serum MMP-1 and MMP-3. Prog. Mod. Biomed.20 (16), 3117–3120. 10.13241/j.cnki.pmb.2020.16.025
67
LiZ.LiD. (1998). Progress in the research on chemical composition and pharmacology of radis Achyranthes bidentata. Zhongguo Zhong Xi Yi Jie He Za Zhi18 (12), 756–758.
68
LiangL.DuC.LiangD. (2022). The research progress on extraction and determination methods of chemical constituents in cyathulae radix and achyranthis bidentatae radixpolysaccharides. J. Anhui Agric. Sci.50 (09), 12–14.
69
LinC. M.ChangH.ChenY. H.LiS. Y.WuI. H.ChiuJ. H. (2006). Protective role of wogonin against lipopolysaccharide-induced angiogenesis via VEGFR-2, not VEGFR-1. Int. Immunopharmacol.6 (11), 1690–1698. 10.1016/j.intimp.2006.07.003
70
LinF.LuoX.TsunA.LiZ.LiD.LiB. (2015). Kaempferol enhances the suppressive function of treg cells by inhibiting FOXP3 phosphorylation. Int. Immunopharmacol.28 (2), 859–865. 10.1016/j.intimp.2015.03.044
71
LinY. J.AnzagheM.SchülkeS. (2020). Update on the Pathomechanism, Diagnosis, and Treatment Options for Rheumatoid Arthritis. Cells, 9 (4), 859–865. 10.3390/cells9040880
72
LiuJ.PanJ.WangY.LinD.ShenD.YangH.et al (2013). Component analysis of Chinese medicine and advances in fuming-washing therapy for knee osteoarthritis via unsupervised data mining methods. J. Tradit. Chin. Med.33 (5), 686–691. 10.1016/s0254-6272(14)60043-1
73
LiuK. (2017). Clinical study on fengshi maqian tablets combined with methotrexate in treatment of rheumatoid arthritis. Drugs and Clin.32 (8), 1552–1555. 10.7501/j.issn.1674-5515.2017.08.037
74
LiuR.HaoD.XuW.LiJ.LiX.ShenD.et al (2019). β-Sitosterol modulates macrophage polarization and attenuates rheumatoid inflammation in mice. Pharm. Biol.57 (1), 161–168. 10.1080/13880209.2019.1577461
75
LiuS.MaH.ZhangH.DengC.XinP. (2021a). Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. Clin. Immunol.230, 108793. 10.1016/j.clim.2021.108793
76
LiuS. F.ZhaoY.JiaB.LiJ. F. (2021b). Clinical study of biqi capsule combined with methotrexate for treatment of rheumatoid arthritis. Drug Eval. Res.44 (8), 1727–1731. 10.7501/j.issn.1674-6376.2021.08.024
77
LiuZ.GuoS.DongQ. (2020). Nobiletin suppresses IL-21/IL-21 receptor-mediated inflammatory response in MH7A fibroblast-like synoviocytes (FLS): an implication in rheumatoid arthritis. Eur. J. Pharmacol.875, 172939. 10.1016/j.ejphar.2020.172939
78
LuA. (2025). Elevating traditional Chinese medicine in global health research: the case for Chinese herbal medicine formulas in mainstream therapeutics. Innovation6 (4), 100811. 10.1016/j.xinn.2025.100811
79
LvL.LvJ.SunQ.MeiM.GuW.WangH. (2023). Meta-analysis of clinical effect and safety of biqi capsule combined with methotrexate or single use in treatment of rheumatoid arthritis. Liaoning J. Traditional Chin. Med.50 (07), 8–15+253. 10.13192/j.issn.1000-1719.2023.07.002
80
MaM.LiX.LiY. (2024). Effects of sanhan chushi decoction combined with Western medicine on DAS28 and HAQ scores in patients with elderly-onset rheumatoid arthritis. Liaoning J. Traditional Chin. Med.51 (09), 80–83. 10.13192/j.issn.1000-1719.2024.09.022
81
MaX.LiuJ.YangL.ZhangB.DongY.ZhaoQ. (2018). Cynomorium songaricum prevents bone resorption in ovariectomized rats through RANKL/RANK/TRAF6 mediated suppression of PI3K/AKT and NF-κB pathways. Life Sci.209, 140–148. 10.1016/j.lfs.2018.08.008
82
MaedaK.YoshidaK.NishizawaT.OtaniK.YamashitaY.OkabeH.et al (2022). Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int. J. Mol. Sci.23 (5), 2871. 10.3390/ijms23052871
83
MarahlehA.KitauraH.OhoriF.KishikawaA.OgawaS.ShenW. R.et al (2019). TNF-α directly enhances osteocyte RANKL expression and promotes osteoclast formation. Front. Immunol.10, 2925. 10.3389/fimmu.2019.02925
84
MarkovicsA.RosenthalK. S.MikeczK.CarambulaR. E.CiemielewskiJ. C.ZimmermanD. H. (2021). Restoring the balance between pro-inflammatory and anti-inflammatory cytokines in the treatment of rheumatoid arthritis: new insights from animal models. Biomedicines10 (1), 44. 10.3390/biomedicines10010044
85
Martel-PelletierJ.PelletierJ. P.FahmiH. (2003). Cyclooxygenase-2 and prostaglandins in articular tissues. Semin. Arthritis Rheum.33 (3), 155–167. 10.1016/s0049-0172(03)00134-3
86
MengX.WangZ.LiangS.TangZ.LiuJ.XinY.et al (2019). Hepatoprotective effect of a polysaccharide from Radix cyathulae officinalis kuan against CCl(4)-induced acute liver injury in rat. Int. J. Biol. Macromol.132, 1057–1067. 10.1016/j.ijbiomac.2019.04.018
87
MunS. H.ParkP. S. U.Park-MinK. H. (2020). The M-CSF receptor in osteoclasts and beyond. Exp. Mol. Med.52 (8), 1239–1254. 10.1038/s12276-020-0484-z
88
NagyG.KonczA.TelaricoT.FernandezD.ErsekB.BuzásE.et al (2010). Central role of nitric oxide in the pathogenesis of rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res. Ther.12 (3), 210. 10.1186/ar3045
89
NeogM. K.Joshua PragasamS.KrishnanM.RasoolM. (2017). p-Coumaric acid, a dietary polyphenol ameliorates inflammation and curtails cartilage and bone erosion in the rheumatoid arthritis rat model. Biofactors43 (5), 698–717. 10.1002/biof.1377
90
NygaardG.FiresteinG. S. (2020). Restoring synovial homeostasis in rheumatoid arthritis by targeting fibroblast-like synoviocytes. Nat. Rev. Rheumatol.16 (6), 316–333. 10.1038/s41584-020-0413-5
91
OdobasicD.YangY.MuljadiR. C.O'SullivanK. M.KaoW.SmithM.et al (2014). Endogenous myeloperoxidase is a mediator of joint inflammation and damage in experimental arthritis. Arthritis Rheumatol.66 (4), 907–917. 10.1002/art.38299
92
PanD.LiN.LiuY.XuQ.LiuQ.YouY.et al (2018). Kaempferol inhibits the migration and invasion of rheumatoid arthritis fibroblast-like synoviocytes by blocking activation of the MAPK pathway. Int. Immunopharmacol.55, 174–182. 10.1016/j.intimp.2017.12.011
93
PangY.LiuL.MuH.Priya VeeraraghavanV. (2021). Nobiletin promotes osteogenic differentiation of human osteoblastic cell line (MG-63) through activating the BMP-2/RUNX-2 signaling pathway. Saudi J. Biol. Sci.28 (9), 4916–4920. 10.1016/j.sjbs.2021.06.070
94
ParkH. Y.LimH.KimH. P.KwonY. S. (2011). Downregulation of matrix metalloproteinase-13 by the root extract of Cyathula officinalis kuan and its constituents in IL-1β-treated chondrocytes. Planta Med.77 (13), 1528–1530. 10.1055/s-0030-1270834
95
ParkJ. Y.PillingerM. H.AbramsonS. B. (2006). Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. Clin. Immunol.119 (3), 229–240. 10.1016/j.clim.2006.01.016
96
PengS.HuC.LiuX.LeiL.HeG.XiongC.et al (2020). Rhoifolin regulates oxidative stress and proinflammatory cytokine levels in Freund's adjuvant-induced rheumatoid arthritis via inhibition of NF-κB. Braz J. Med. Biol. Res.53 (6), e9489. 10.1590/1414-431x20209489
97
PonzettiM.RucciN. (2021). Osteoblast differentiation and signaling: established concepts and emerging topics. Int. J. Mol. Sci.22 (13), 6651. 10.3390/ijms22136651
98
QianK.ZhengX. X.WangC.HuangW. G.LiuX. B.XuS. D.et al (2021). β-Sitosterol inhibits rheumatoid synovial angiogenesis through suppressing VEGF signaling pathway. Front. Pharmacol.12, 816477. 10.3389/fphar.2021.816477
99
RuJ.LiP.WangJ.ZhouW.LiB.HuangC.et al (2014). TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J. Cheminform6, 13. 10.1186/1758-2946-6-13
100
ShiJ. H.SunS. C. (2018). Tumor necrosis factor receptor-associated factor regulation of nuclear factor κB and mitogen-activated protein kinase pathways. Front. Immunol.9, 1849. 10.3389/fimmu.2018.01849
101
ShimazuK.FukumitsuS.IshijimaT.ToyodaT.NakaiY.AbeK.et al (2019). The anti-arthritis effect of olive-derived maslinic acid in mice is due to its promotion of tissue formation and its anti-inflammatory effects. Mol. Nutr. Food Res.63 (3), e1800543. 10.1002/mnfr.201800543
102
SialN. T.MalikA.IqbalU.MehmoodM. H.RehmanM. F. U. (2024). Novel antiarthritic mechanisms of azelaic acid against CFA-Induced arthritis in rats by modulating pro- and anti-inflammatory cytokines network. Inflammopharmacology32, 2445–2462. 10.1007/s10787-024-01512-0
103
SpillerF.Oliveira FormigaR.Fernandes da Silva CoimbraJ.Alves-FilhoJ. C.CunhaT. M.CunhaF. Q. (2019). Targeting nitric oxide as a key modulator of Sepsis, arthritis and pain. Nitric Oxide89, 32–40. 10.1016/j.niox.2019.04.011
104
SuH. M.XuX. Y.ChengL. (2020). Effect of celecoxib combined with tongbi tablet on rheumatoid arthritis. Chin. Foreign Med. Res.18 (26), 17–19. 10.14033/j.cnki.cfmr.2020.26.006
105
SunY.ZhaoD. L.LiuZ. X.SunX. H.LiY. (2017). Beneficial effect of 20-hydroxyecdysone exerted by modulating antioxidants and inflammatory cytokine levels in collagen-induced arthritis: a model for rheumatoid arthritis. Mol. Med. Rep.16 (5), 6162–6169. 10.3892/mmr.2017.7389
106
TangM.ZengY.PengW.XieX.YangY.JiB.et al (2022). Pharmacological aspects of natural quercetin in rheumatoid arthritis. Drug Des. Devel Ther.16, 2043–2053. 10.2147/dddt.s364759
107
TangQ. Y.KukitaT.UshijimaY.KukitaA.NagataK.SandraF.et al (2006). Regulation of osteoclastogenesis by simon extracts composed of caffeic acid and related compounds: successful suppression of bone destruction accompanied with adjuvant-induced arthritis in rats. Histochem Cell Biol.125 (3), 215–225. 10.1007/s00418-005-0062-4
108
TaoY.DuY.LiW.CaiB. (2018). Development and validation of an UHPLC-MS/MS approach for simultaneous quantification of five bioactive saponins in rat plasma: application to a comparative pharmacokinetic study of aqueous extracts of raw and salt-processed Achyranthes bidentata. J. Pharm. Biomed. Anal.151, 164–169. 10.1016/j.jpba.2017.12.024
109
TaoY.HuangS.YanJ.CaiB. (2019a). Determination of major components from radix Achyranthes bidentate using ultra high performance liquid chromatography with triple Quadrupole tandem mass spectrometry and an evaluation of their anti-osteoporosis effect in vitro. J. Sep. Sci.42 (13), 2214–2221. 10.1002/jssc.201900146
110
TaoY.YanJ.CaiB. (2019b). A liquid chromatography-tandem mass spectrometry approach for study the tissue distributions of five components of crude and salt-processed radix achyranthes in rats. Biomed. Chromatogr.33 (6), e4483. 10.1002/bmc.4483
111
TarditoS.MartinelliG.SoldanoS.PaolinoS.PaciniG.PataneM.et al (2019). Macrophage M1/M2 polarization and rheumatoid arthritis: a systematic review. Autoimmun. Rev.18 (11), 102397. 10.1016/j.autrev.2019.102397
112
TengL.YangL.FuQ. (2022). Isolation and identification of chemical constituents from the roots of Cyathula officinalis. J. Chin. Med. Mater.45 (01), 84–88. 10.13863/j.issn1001-4454.2022.01.015
113
TieR.JiL.NanY.WangW.LiangX.TianF.et al (2013). Achyranthes bidentata polypeptides reduces oxidative stress and exerts protective effects against myocardial ischemic/reperfusion injury in rats. Int. J. Mol. Sci.14 (10), 19792–19804. 10.3390/ijms141019792
114
TsikasD.MikuteitM. (2022). N-Acetyl-L-cysteine in human rheumatoid arthritis and its effects on nitric oxide (NO) and malondialdehyde (MDA): analytical and clinical considerations. Amino Acids54 (9), 1251–1260. 10.1007/s00726-022-03185-x
115
TuJ.HongW.ZhangP.WangX.KörnerH.WeiW. (2018). Ontology and function of fibroblast-like and macrophage-like synoviocytes: how do they talk to each other and can they be targeted for rheumatoid arthritis therapy?Front. Immunol.9, 1467. 10.3389/fimmu.2018.01467
116
van der WoudeD.van der Helm-van MilA. H. M. (2018). Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best. Pract. Res. Clin. Rheumatol.32 (2), 174–187. 10.1016/j.berh.2018.10.005
117
WangH.QiJ.LiL.WuT.WangY.WangX.et al (2015). Inhibitory effects of chikusetsusaponin IVa on lipopolysaccharide-induced pro-inflammatory responses in THP-1 cells. Int. J. Immunopathol. Pharmacol.28 (3), 308–317. 10.1177/0394632015589519
118
WangH.YangD.JiangS.RenY.WuL.WangZ.et al (2023). Simultaneous determination of four phytoecdysteroids by LC-MS/MS: application to a comparative pharmacokinetic study in normal and adjuvant arthritis rats after oral administration of C. officinalis kuan phytoecdysteroids extract. Xenobiotica53 (12), 634–643. 10.1080/00498254.2023.2270741
119
WangJ.ZhaoQ. (2019). Kaempferitrin inhibits proliferation, induces apoptosis, and ameliorates inflammation in human rheumatoid arthritis fibroblast-like synoviocytes. Phytother. Res.33 (6), 1726–1735. 10.1002/ptr.6364
120
WangT.DaiY.DunY.ZhangC.WanJ.DengL.et al (2014). Chikusetsusaponin V inhibits inflammatory responses via NF-κB and MAPK signaling pathways in LPS-Induced RAW 264.7 macrophages. Immunopharmacol. Immunotoxicol.36 (6), 404–411. 10.3109/08923973.2014.960088
121
WangW.SunW.JinL. (2017). Caffeic acid alleviates inflammatory response in rheumatoid arthritis fibroblast-like synoviocytes by inhibiting phosphorylation of IκB kinase α/β and IκBα. Int. Immunopharmacol.48, 61–66. 10.1016/j.intimp.2017.04.025
122
WangX.KongY.LiZ. (2024a). Advantages of Chinese herbal medicine in treating rheumatoid arthritis: a focus on its anti-inflammatory and anti-oxidative effects. Front. Med. (Lausanne)11, 1371461. 10.3389/fmed.2024.1371461
123
WangX.SunB.WangY.GaoP.SongJ.ChangW.et al (2024b). Research progress of targeted therapy regulating Th17/Treg balance in bone immune diseases. Front. Immunol.15, 1333993. 10.3389/fimmu.2024.1333993
124
WangY.ShenW.YangL.ZhaoH.GuW.YuanY. (2013). The protective effects of Achyranthes bidentata polypeptides on rat sciatic nerve crush injury causes modulation of neurotrophic factors. Neurochem. Res.38 (3), 538–546. 10.1007/s11064-012-0946-3
125
WangY.WuH.DengR. (2021). Angiogenesis as a potential treatment strategy for rheumatoid arthritis. Eur. J. Pharmacol.910, 174500. 10.1016/j.ejphar.2021.174500
126
WangY.YaoC.WangM.LiJ.LiZ.ZhangJ.et al (2022b). Systematical characterization and comparison of saponins in Achyranthes bidentata blume and its three analogous species. Phytochem. Anal.33 (5), 766–775. 10.1002/pca.3128
127
WangY.-Y.LiJ.-Y.YaoC.-L.ZhangJ.-Q.YuY.YaoS.et al (2022a). Deep chemical identification of phytoecdysteroids in Achyranthes bidentata blume by UHPLC coupled with linear ion trap-orbitrap mass spectrometry and targeted isolation. Chin. J. Nat. Med.20 (7), 551–560. 10.1016/s1875-5364(22)60185-7
128
WangZ.WuJ.LiD.TangX.ZhaoY.CaiX.et al (2020). Traditional Chinese medicine biqi capsule compared with leflunomide in combination with methotrexate in patients with rheumatoid arthritis: a randomized controlled trial. Chin. Med.15, 36. 10.1186/s13020-020-00319-9
129
WójcikP.GęgotekA.ŽarkovićN.SkrzydlewskaE. (2021). Oxidative stress and lipid mediators modulate immune cell functions in autoimmune diseases. Int. J. Mol. Sci.22 (2), 723. 10.3390/ijms22020723
130
WuF.GaoJ.KangJ.WangX.NiuQ.LiuJ.et al (2021a). B cells in rheumatoid arthritis:pathogenic mechanisms and treatment prospects. Front. Immunol.12, 750753. 10.3389/fimmu.2021.750753
131
WuZ.MaD.YangH.GaoJ.ZhangG.XuK.et al (2021b). Fibroblast-like synoviocytes in rheumatoid arthritis: surface markers and phenotypes. Int. Immunopharmacol.93, 107392. 10.1016/j.intimp.2021.107392
132
XieB. P.ShiL. Y.LiJ. P.ZengY.LiuW.TangS. Y.et al (2019). Oleanolic acid inhibits RANKL-Induced osteoclastogenesis via ER alpha/miR-503/RANK signaling pathway in RAW264.7 cells. Biomed. Pharmacother.117, 109045. 10.1016/j.biopha.2019.109045
133
XieW.YangH.GuoC.XieR.YuG.LiY. (2023). Integrated network pharmacology and experimental validation approach to investigate the mechanisms of stigmasterol in the treatment of rheumatoid arthritis. Drug Des. Devel Ther.17, 691–706. 10.2147/dddt.S387570
134
XinY.YuanQ.LiuC.ZhangC.YuanD. (2020). MiR-155/GSK-3β mediates anti-inflammatory effect of chikusetsusaponin IVa by inhibiting NF-κB signaling pathway in LPS-Induced RAW264.7 cell. Sci. Rep.10 (1), 18303. 10.1038/s41598-020-75358-1
135
XuF.ShenC.ZhangS.LiuY.LiuD.KuangY.et al (2024). Coptisine inhibits aggressive and proliferative actions of fibroblast like synoviocytes and exerts a therapeutic potential for rheumatoid arthritis. Int. Immunopharmacol.128, 111433. 10.1016/j.intimp.2023.111433
136
XuG.LeiH.YuanQ.ChenH.SuJ. (2021). Inhibition of chikusetsusaponin IVa on inflammatory responses in RAW264.7 cell line via MAPK pathway. Z Naturforsch C J. Biosci.76 (3-4), 103–110. 10.1515/znc-2019-0107
137
XuH. L.ChenG. H.WuY. T.XieL. P.TanZ. B.LiuB.et al (2022). Ginsenoside Ro, an oleanolic saponin of Panax ginseng, exerts anti-inflammatory effect by direct inhibiting toll like receptor 4 signaling pathway. J. Ginseng Res.46 (1), 156–166. 10.1016/j.jgr.2021.05.011
138
YanL.SongY.AiZ.LiH.YangM.ZhuG.et al (2024). Comparation of differences in chemical components of different varieties of Achyranthes bidentata based on UPLC-Q-TOF-MS/MS technology combined with multivariate statistical analysis. Chin. Traditional Herb. Drugs55 (07), 2160–2174.
139
YanM.SuJ.LiY. (2020). Rheumatoid arthritis-associated bone erosions: evolving insights and promising therapeutic strategies. Biosci. Trends14 (5), 342–348. 10.5582/bst.2020.03253
140
YangG.LiS.YuanL.YangY.PanM. H. (2017). Effect of nobiletin on the MAPK/NF-κB signaling pathway in the synovial membrane of rats with arthritis induced by collagen. Food Funct.8 (12), 4668–4674. 10.1039/c7fo01311f
141
YangH.LiuC.LinX.LiX.ZengS.GongZ.et al (2024). Wogonin inhibits the migration and invasion of fibroblast-like synoviocytes by targeting PI3K/AKT/NF-κB pathway in rheumatoid arthritis. Arch. Biochem. Biophys.755, 109965. 10.1016/j.abb.2024.109965
142
YangL.JiangH.YanM.XingX.GuoX.YangB.et al (2018). UHPLC-MS/MS quantification combined with chemometrics for comparative analysis of different batches of raw, wine-processed, and salt-processed Radix achyranthis bidentatae. Molecules23 (4), 758. 10.3390/molecules23040758
143
YangL. F.TengL.HuangY. H.TangM.LiaoW.FuQ. (2022). Undescribed ecdysteroids and phenolic glycosides from the roots of Cyathula officinalis kuan and their anti-inflammatory activity in LPS-Induced RAW 264.7 macrophages in vitro. Phytochemistry196, 113101. 10.1016/j.phytochem.2022.113101
144
YangM.ZhuL. (2024). Osteoimmunology: the crosstalk between T cells, B cells, and osteoclasts in rheumatoid arthritis. Int. J. Mol. Sci.25 (5), 2688. 10.3390/ijms25052688
145
YangX.ChangY.WeiW. (2020). Emerging role of targeting macrophages in rheumatoid arthritis: focus on polarization, metabolism and apoptosis. Cell Prolif.53 (7), e12854. 10.1111/cpr.12854
146
YaoZ.GettingS. J.LockeI. C. (2021). Regulation of TNF-induced osteoclast differentiation. Cells11 (1), 132. 10.3390/cells11010132
147
YooS. R.JeongS. J.LeeN. R.ShinH. K.SeoC. S. (2017). Quantification analysis and in vitro anti-inflammatory effects of 20-Hydroxyecdysone, momordin Ic, and oleanolic acid from the fructus of kochia scoparia. Pharmacogn. Mag.13 (51), 339–344. 10.4103/0973-1296.211023
148
YoonH. Y.LeeE. G.LeeH.ChoI. J.ChoiY. J.SungM. S.et al (2013). Kaempferol inhibits IL-1β-induced proliferation of rheumatoid arthritis synovial fibroblasts and the production of COX-2, PGE2 and MMPs. Int. J. Mol. Med.32 (4), 971–977. 10.3892/ijmm.2013.1468
149
ZhangD.LyuJ. T.ZhangB.ZhangX. M.JiangH.LinZ. J. (2020a). Comparative efficacy, safety and cost of oral Chinese patent medicines for rheumatoid arthritis: a Bayesian network meta-analysis. BMC Complement. Med. Ther.20 (1), 210. 10.1186/s12906-020-03004-4
150
ZhangF.TanakaH.KawatoT.KitamiS.NakaiK.MotohashiM.et al (2011a). Interleukin-17A induces cathepsin K and MMP-9 expression in osteoclasts via celecoxib-blocked prostaglandin E2 in osteoblasts. Biochimie93 (2), 296–305. 10.1016/j.biochi.2010.10.001
151
ZhangJ. F.FuW. M.HeM. L.XieW. D.LvQ.WanG.et al (2011b). MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol.8 (5), 829–838. 10.4161/rna.8.5.16043
152
ZhangJ. H.ZhouS. H.YangD.GongN. N. (2020b). Observation on clinical effects of simiao tang and leflunomide in treating rheumatoid arthritis of damp-heat obstruction pattern. West. J. Traditional Chin. Med.33 (8), 8–11. 10.12174/j.issn.1004-6852.2020.08.03
153
ZhangL.WenC. (2021). Osteocyte dysfunction in joint homeostasis and osteoarthritis. Int. J. Mol. Sci.22 (12), 6522. 10.3390/ijms22126522
154
ZhangL. B.YanY.MaR.LiD. X.YinW. F.TaoQ. W.et al (2024). Integrated phytochemistry and network pharmacology analysis to reveal effective substances and mechanisms of bushen quhan zhiwang decoction in the treatment of rheumatoid arthritis. J. Ethnopharmacol.325, 117897. 10.1016/j.jep.2024.117897
155
ZhangX.ZhangJ.ChenM. (2023). Clinical effects of qushi zhitong pills on patients with rheumatoid arthritis. Chin. Tradit. Pat. Med.45 (12), 3950–3953.
156
ZhengC.LiD.ZhanW.HeK.YangH. (2020). Downregulation of SENP1 suppresses LPS-Induced macrophage inflammation by elevating Sp3 SUMOylation and disturbing Sp3-NF-κB interaction. Am. J. Transl. Res.12 (11), 7439–7448.
157
ZhengW.LuX.FuZ.ZhangL.LiX.XuX.et al (2016). Identification of candidate synovial membrane biomarkers after Achyranthes aspera treatment for rheumatoid arthritis. Biochim. Biophys. Acta1864 (3), 308–316. 10.1016/j.bbapap.2015.12.010
158
ZhengY.WeiK.JiangP.ZhaoJ.ShanY.ShiY.et al (2024). Macrophage polarization in rheumatoid arthritis: signaling pathways, metabolic reprogramming, and crosstalk with synovial fibroblasts. Front. Immunol.15, 1394108. 10.3389/fimmu.2024.1394108
159
ZhongC.YangJ.LuY.XieH.ZhaiS.ZhangC.et al (2020). Achyranthes bidentata polysaccharide can safely prevent NSCLC metastasis via targeting EGFR and EMT. Signal Transduct. Target Ther.5 (1), 178. 10.1038/s41392-020-00289-2
160
ZhouM.JinW.LiP.WangR.GuoX. (2023). Traditional Chinese medicine in the treatment of hemorrhoids-a review of preparations used and their mechanism of action. Front. Pharmacol.14, 1270339. 10.3389/fphar.2023.1270339
161
ZhuW.LiX.FangS.ZhangX.WangY.ZhangT.et al (2015). Anti-citrullinated protein antibodies induce macrophage subset disequilibrium in RA patients. Inflammation38 (6), 2067–2075. 10.1007/s10753-015-0188-z
Summary
Keywords
rheumatoid arthritis, Achyranthes bidentata Blume, Cyathula officinalis K.C.Kuan, pharmacology, pharmacokinetics
Citation
Zhang L-B, Yan Y, Lian W-W, Zhou W, Xia C-Y, He J and Xu Y (2025) Effects and molecular mechanisms of Achyranthes bidentata Blume and Cyathula officinalis K.C. Kuan in the treatment of rheumatoid arthritis. Front. Pharmacol. 16:1619776. doi: 10.3389/fphar.2025.1619776
Received
28 April 2025
Accepted
07 July 2025
Published
24 July 2025
Volume
16 - 2025
Edited by
Dongyi He, Shanghai Guanghua Rheumatology Hospital, China
Reviewed by
Li-Hua Mu, People’s Liberation Army General Hospital, China
Zheng Liu, Xiangtan Central Hospital, China
Ping Yan, Guangzhou University of Chinese Medicine, China
Updates
Copyright
© 2025 Zhang, Yan, Lian, Zhou, Xia, He and Xu.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jun He, 15010297582@126.com; Yuan Xu, xuyuan2004020@163.com
†These authors have contributed equally to this work and share first authorship
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.